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ABSTRACT 
Furosemide (Lasix®), abbreviated asFR and also known as frusemide, is a drug used for renal 
problems and treatment of cardiac edema. Various polymorphic forms of furosemide, dependent 
upon the method of preparation and thermal treatment, have been reported. The main thermal 
decomposition product offurosemide has been identified as saluamine. The dissolution properties 
of furosemide have also been reported to be improved by complexation with beta-cyclodextrin. 
Photostabilities of the different crystal forms have been studied . 
Differential scanning calorimetry (DSC) and thermogravimetry (TG) have been used to examine 
the thermal behaviour of furosemide itself and of its physical and kneaded mixtures with beta-
cyclodextrin (BCD) and gamma-cyclodextrin (GCD). There is strong evidence from DSC that 
complex format ion between FR and GCD occurs. This is supported by IR and XRD data. 
Decreases in the intensity and broadening of the characteristic carbonyl (1660 cm'l) and amine 
(1588 cm'l) bands in the kneaded mixture, compared to the physical mixture, were observed with 
IR. X-ray diffraction resLllts fo r the 1:3 molar ratio FRlGCD kneaded mixture showed a halo 
diffraction pattern characteristic. of an amorphous solid and did not resemble patterns from the 
drug, or the gamma,cyclodextrin, or the physical mixture. 
Photostability studies have been conducted on solid furosemide and its mixtures with GCD or 
BCD. An HPLC method was developed to determine the amount of drug remaining after 
exposure and the presence of any degradants . Results indicated that about 10 % degradation of 
the drug occurred during exposure for 16 hours at 550 W/m2, with the appearance of polar 
degradants . 
AlthoughIR and DSC results for the 1:3 molar ratio FRlGCD kneaded mixture showed a probable 
strong interaction between FR and GCD, the photostability of FR was decreased. The 1 :3 molar 
ratio FRlBCD kneaded mixture showed less photo-degradation than the 1:3 molar ratio FRlGCD 
mixture under similar condi tions, suggesting that inclusion of the drug molecule (FR) is different 
in the two cyclodextrins. 
1 
Chapter 1 
1. INTRODUCTION 
1.1. Characteristics of furosemide (FR) and its clinical uses 
Furosemide [1, 2] is a short-acting loop diuretic, Imown by the trade name ofLasix® [3] and 
sometimes referred to as fiusemide. It is effective in the treatment of the edema due to hepatic, 
renal or cardiac failure, as well as edema due to burns. It can also be used to reduce urinary 
output if the patient has pregnancy complications; for treatment of hypertension, and as an 
adjunct in hypertensive crisis. Furosemide acts on the kidney to increase the body's loss of water 
and assorted minerals and electrolytes (e.g. salts of potassium, calcium and magnesium). 
Accumulation offluids in the body tissues is thus decreased by removing water through excretion. 
The drug is available in two forms : as an injectable drug which is used in cases of acute heart-
failure crisis; Dr in oral tablet form which is generally adequate for continued management after 
stabilization. Its toxicity involves abnormalities in fluid and electrolyte balance. Hyperuricemia 
and gastrointestinal side-effects are also commonly observed [4]. 
H 
CI 
I 0 N-CH~ 
OOH 
Figure 1.1 Furosemide (FR) 
The empirical formula offurosemide (abbreviated to FR) is C12HIlClN20 ,S and it has a molecular 
mass of330.8 glmo!. The elemental composition is C 43 .57 %, H 3.35 %, CllO.72 %, N 8.47 
%,024.19 % and S 9.70 %. It is a slightly yellow, crystalline powder, odourless and is almost 
tasteless. 
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Aqueous solutions of furosemide [5] have pH's between 8.9 and 9.3. Furosemide is usually 
characterized more by its pharmacological than its chemical similarities. It is regarded as a 
derivative of anthranilic acid, or o-aminobenzoic acid (see Figure 1.4). Because the drug 
molecule possesses a free carbonyl group, it is known to be a stronger acid than the thiazide 
diuretics [6] . The drug is excreted mostly unchanged, although a small amount of metabolism can 
take place on the furan ring (7]. The drug has a duration of action of about six to eight hours . 
Furosemide is slightly soluble in water, chloroform and diethylether and highly soluble in acetone, 
methanol, dimethyl formamide [8] and solutions of alkali metal hydroxides [9]. The drug is 
known to be unstable to both heat and light and has to be stored at temperatures of IS-30°C and 
must be protected from light, because exposure of the tablets may cause discolouration. 
Discoloured tablets are not allowed to be dispensed to patients [5]. 
The bioavailability of FR has been known to be poor and highly variable in oral dosage forms. 
This poor bioavailability has been speculated to be due to a variety of reasons; including poor 
aqueous solubility, site-specific absorption (which has shown that the stomach has a greater 
absorptive area for furosemide than the intestine, despite the smaller absorptive area in the 
stomach) and pre-systematic metabolism [10, 11]. Additional reasons include its instability in 
gastric and or duodenal juices [12], inter-and intra-patient variability, as well as formulation 
differences [13]. 
Because the drug is known to be only slightly soluble in water, improvement of its dissolution 
properties is essential. The in vitro dissolution behavior of a drug is closely related to its 
bioavailability [14]. Proudfoot [15] states that the rate at which a sparingly soluble drug 
dissolves in the gastrointestinal fluids may be the slowest step in the sequence of events leading 
to the appearance of the drug intact in the systematic circulation. Drug absorption and 
bioavailability are also known to depend on how rapidly the drug dissolves in the gastrointestinal 
fluids . Therefore, factors which influence the rate of dissolution will also influence the 
bioavailability of the drug. 
3 
Noyes-Whitney's equation [13) can be used to describe the process of dissolution in drugs: 
dmIdt = ((D A) I h}(C,-C) 
where dm Idt = mass rate of dissolution, D = diffusion coefficient of the drug in solution in the 
gastrointestinal fluids , A = surface area of drug particles in contact with the gastrointestinal fluids, 
h = thickness of the diffusion layer around the drug particle, C, = saturation solubility of the drug 
in the diffusion layer and C = the concentration of the drug in solution in the bulk of the 
gastrointestinal fluid. 
Furosemide is known to absorb ultraviolet light at 275 and 345 nm and to fluoresce at 405 to 417 
nm. The fluorescence is pH dependent [10). 
Bundgaard, N0fgaard and Nielsen [17) reported that Sturm et al. [16) found that the furylmethyl 
group in the molecule is acid-labile and furosemide has been shown to undergo acid-catalyzed 
hydrolysis in aqueous solution to yield 4-chloro-5-sulpharnoyl-anthranilic acid (saluarnine). 
Beyers et al. [18) reported that decomposition of furosemide occurs before or during melting. The 
degradation products formed were not described. The main thermal decomposition product of 
furosemide was also identified as saluarnine [18). 
4 
C 
r 0 -CH~ 
H,O C~ ....NH -",::::::/" 2 
1// 
H,NO,S '-eOOH 
1 
H"NO,/ 6 
HCI 
• 
1 2 
Figure 1.2 The formation ofsaluamine (2) through acid hydrolysis offurosemide (I), as reported 
by Beyers et al. [18]. 
1.2. Polymorphic forms and thermal behaviour 
The melting range offurosemide has been reported to be 217-222 °c [J9]. This drug was initially 
reported by Doherty and York [19] to have two polymorphic forms : Form I and Form IT. These 
two forms were prepared by recrystallization of corrunercial furosemide, using methanol and 
ethanol solutions, respectively. DSC curves of the compounds showed two endotherms: the first, 
around 136-139 °c, is associated with Form I and is reversible (with LUI = 2.2 kJlmol, or 67 Jig) . 
The second endotherm corresponds to melting with decomposition. Form IT did not show the first 
endotherm around 136-139 °c. Doherty and York proposed that the weak endotherm around 
136-139°C must be a subtle change in molecular conformation and crystal packing. They 
recorded a series of variable temperature FTIR spectra and the results obtained suggested that 
the two forms were discrete crystal structures ofFR and that they did not transform on heating to 
180°C, within the experimental conditions used. 
NMR data also suggested changes in the molecular conformation of the FR molecule in the crystal 
Form IT that were associated with an altered hydrogen-bonding sequence and a different crystal 
packing arrangement, in agreement with their IR and XRD data [19]. 
No thermal route was found for conversion of Form I to Form II. Hot-stage microscopy showed 
an abrupt disintegration of crystals of Form I around 135-140 °c without any sign of melting [19] 
5 
(the extent of the mass loss was not given) . Form II has been reported [19] to have a greater 
dissolution rate in water than Form 1. Further research by AbduJla et al . [6) showed that there are 
three forms offurosemide. FR I was prepared from methanol solution, FR II, which was prepared 
from 5 % ammonia solution and was shown to be an ammonium salt, and FR III, which was 
prepared from n-butanol solution. 
FR ill showed a phase transition at 105 DC to FR 1. The IR spectra ofFR I and FR II differ in the 
regions 3380-3260 cm- I and 1420-1370 cm- l FR I shows a band at 3380 cm-I , characteristic of 
the secondary amine group, and two peaks at 3320 cm- I and 3260 cm- I corresponding to the 
sulfonamide amino group. Spectral changes also occurred in the S02 absorption region 1420-
1370 cm- I , 
Matsuda and Tatsumi [20] obtained further forms of furosemide, Form IV and Form V, on heating 
the other forms to 180 DC. The DSC curve for Form IV was reported (20) to have a sharp 
endotherm at 93 DC, accompanied by a shoulder at J 02 DC, and followed by a slight endotherm at 
143 DC. The TG curve showed a mass loss of 17.3 % of the total mass between 70- 127 DC, 
corresponding to the first endotherm. This suggests that desolvation occurs. The XRD pattern 
of this form, which had been heated once and then cooled, revealed it to be identical with Form 1. 
The second endotherm at J 43 DC was attributed to the resultant Form I undergoing transformation 
to a higher-temperature stable form. The DSC curve of Form V displayed (20) strong and weak 
endotherms at 89 and 139 DC, respectively, with the final melting endotherm at 218 Dc. A 20.5 
% loss in total mass over the temperature range from 89-218 DC, was indicated by the TG curve. 
It was suggested that the endotherm at 89 DC was caused by desolvation, thereby demonstrating 
the close agreement between the observed and theoretical values for a 1: J dioxane solvate, From 
XRD results, Form V was shown to be a solvate with dioxane and to be transformed into Form r 
by desolvation at temperatures above 90 DC. The weak endotherm of Form V around 139 DC was 
found to correspond to that of Form 1, indicating transformation of Form I into a higher-
temperature stable form. An exotherm around 130 DC was also reported in the DSC curve for 
Form 1. 
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The amorphous form of FR, which was also obtained by Matsuda and Tatsumi, was recognized 
as an unstable form [20]. It was prepared by spray drying. The DSC curve of this form showed 
an exotherm at about 103-104 DC and a melting endotherm at 214-215 DC. The cause of the 
exotherm was not determined, due to its small size, but it was found to be correlated with the 
transformation to a higher- temperature stable form, as observed in all the other forms. 
XRD analysis of the amorphous form gave a characteristic halo pattern, instead of sharp 
diffi'action peaks. The infrared spectrum gave broad absorptions throughout the entire range, due 
to the low degree of crystallinity possessed by this form. Matsuda and Tatsumi [20] drew up an 
interconversion scheme for furosemide, showing the transformation relationships and conditions 
for stability of these forms. Byrn et at. [21] redrew and summarized these interconversion routes. 
Form I is the most stable form at room temperature (Figure 1.3) 
DMF 
solvate 
Form II 
Amorphous 
form 
High 
Humidir/ 
Form I 
H:a!ing Cooling 
Form IV 
Dioxane 
solvate 
Form 111 
Figure 1.3 Interconversion scheme for furoserrlide solid forms under various conditions. 
Redrawn by Byrn e/ at. [21] from the scheme of Matsuda and Tatsumi, [20). 
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Beyers et.al. [18] reported that the main thermal decomposition product of furosemide at high 
temperatures (218°C) was saluamine (4·chloro·4·sulfamoylanthranilic). Saluamine was formed 
by cleavage of the C·N bond (see F igure 1. 4) . Cottrell [22] calculated that the experimental 
activation energy of 200 (±2) kJ mol-t, was well below the expected activation energy of247 (± 
4) kJ mo]'! actually needed for the C·N cleavage [22]. This difference was explained as possible 
weakening of the C·N bond through the inductive effect of the fiuan ring and the delocalization 
of the electrons of the aniline nitrogen in the chlorosuphamoyl benzoic acid entity of furosemide 
[18]. 
Lamotte et al. [23] mentioned that, when some of the inter·and intramolecular bonds that form part 
of the hydrogen·bond network involving the sulfonamide groups in furosemide disappear, as in the 
structurally· related decomposition product saluamine, the aqueous solubility increases. Saluarnine 
is approximately 30 times more soluble in water than furosemide, but can still be classified as a 
poorly water·soluble compound [23]. This poor solubility of saluamine was attributed to the 
strong hydrogen bonds between the amine and the carbonyl groups that also exist in furosemide 
[23]. 
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Figure 1.4 The weakening of the C-N bond in furosemide through (a) the negative inductive effect 
of the furan ring on the chlorosuphamoyl entity and (b) deiocaIization of the electrons of the 
aniline nitrogen in the benzoic acid entity, as reported by Beyers et a/. [18]. 
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1.3 Photostability of furosemide 
Matsuda and Tatsumi [20] studied the photostability ofFR tablets prepared from Forms I and III 
and of a powder sample of Form II. The tablet surfaces were exposed to light from a 400 W 
mercury vapour lamp and the colour changes, 6E, of the surfaces with time were measured by 
colorimetry. The darkening process followed a rate equation of the form: 
-dilli/ dt = .t. (LlE)" 
Values ofn for all the polymorphic forms were similar (- l.2 to -1.6). Form I was the most stable. 
Rowbotham et al. [24] reported that ultraviolet irradiation of alkaline solutions of furosemide 
produced 4-chloro-5-sulphoanthranilic acid by oxidation of the sulphamoyl group and hydrolysis 
of the furfuryl group. Moore and Tomat [25] reported complete dechlorination after UV 
irradiation in deoxygenated neutral aqueous solutions. 
Moore and Sithipitaks [26] reported that when methanol solutions of furosemide were irradiated 
with 365 nm UV light, photoreduction to N-furfuryl-5-saluamine occurred. Yahya et al. [26] have 
shown that aqueous furosemide solutions, stored in burette administration sets, are stable over a 
48 hour period when exposed to direct daylight! fluorescent strip room lighting, but decomposed 
with a half-life of about 4 hours when exposed to sunlight. 
Neil et al. [28] found that furosemide solutions were stable when stored in normal daylight. 
Bundgaard, Nlilrgaard and Nielsen [17] suggested that the photostability of furosemide may be a 
function ofthe degree of ionization of its carboxylic acid group (i.e. solution pH) such that the un-
ionized species, resembling the esters in terms of inductive effect, might be much more unstable 
towards photolysis than the ionized form. During the development of ester prodrugs of 
furosemide, they noted the extremely high susceptibility of furosemide esters to undergo 
photodegradation in aqueous solutions exposed to normal conditions of artificial light or daylight. 
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1.4 Mixtures of cyc10dextrins (CDs) with furosemide 
Ozdermir and Ordu [29] used DSC to study kneaded and physical mixtures of FR with beta-
cyclodextrin (BCD) and reported the following. DSC curves for BCD displayed no peaks in the 
temperature range between 40°C and 300°C, while FR exhibited its characteristic endotherm 
associated with the melting of the drug at 226°C. For the kneaded mixtures, the melting 
endotherm ofFR in the DSC curve disappeared and the physical mix had a less intense endotherm. 
The absence of the peak in the DSC curves may be considered as a strong indication that inclusion 
of the drug in the BCD cavity had occurred . 
IR spectra of the mixtures showed modifications of the carbonyl stretch at 1671 cm-' ; the amide 
stretch at 1596 cm-' ; the sulfonamide stretch at 1322 cm-' ; and the chloride stretch at 582 cm-' . 
Mixtures were stored for 9 months and no changes in the aged samples could be identified from 
the DSC curves. 
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Chapter 2 
2. THERMAL ANALYSIS TECHNIQUES AND THEIR USES 
2.1 Thermal analysis techniques 
2.1. J Definition 
Thermal analysis (TA) [32] is the term used to describe those analytical techniques that measure 
some property of a sample as a function of temperature or time while the sample, in a controlled 
atmosphere, is subjected to a temperature programme. This programme may consist of a series 
of preselected segments in which the sample is heated or cooled at a constant rate or held at a 
constant temperature. The atmosphere surrounding the sample is important and may consist of 
inert or reactive gases. 
2. 1. 2 Differential Scanning Calorimetry, DSC 
A differential scanning calorimeter measures the difference between the rate of heat flow (measured 
in watts (W) or milliwatts (m W)) to the sample and to a reference pan that are subjected to the 
same temperature programme. If the power supplied is integrated with respect to time, then a 
quantity of energy is obtained which may be expressed in units of mW s = mI. If the sample 
absorbs energy, the enthalpy change is positive and the process is called endothermic. If the sample 
liberates energy, then the enthalpy change is negative and the process is said to be exothermic. 
DSC measurements provide information on thermal events which are characterized by enthalpy 
changes, such as melting, crystallization, solid-solid transitions and chemical reactions. Because 
DSC measurements are based on measurements of heat capacity, changes in heat capacity, such 
as that which occurs at the glass transition, can also be determined. 
2. 1.3 Differential Thermal Analysis, DTA 
This technique is qualitatively similar to DSC, except that DT A instruments measure the 
temperature difference, .6.T, between the sample and the reference [30, 31]. Because of their 
simpler construction, more reliable quantitative information can usually be obtained from DSC. 
DTA instruments can usually be used to higher temperatures than DSC instruments [32]. 
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2.1.4 Thermogravimetry, TG (also refened to as TGA) 
In thermogravimetry, the mass of a sample which is subjected to a temperature programme is 
measured. The measurement is performed in a defined atmosphere, usually in inert conditions 
(nitrogen), or in an oxidative environment (air or oxygen). The mass is measured with a sensitive 
electronic balance. Interfering buoyancy or gas-flow effects are compensated for by a blank curve 
correction. Volatile components formed from the sample are also sometimes analysed by evolved 
gas analysis (EGA), (see below). TG can provide information on the content of volatile 
components, such as solvents or water and on decomposition behaviour. 
2.1.5 Evolved Gas Analysis, EGA 
This is the term given to the investigation ofthe gases or volatile components that may be liberated 
from the sample during thermal analysis. The analysis of these components is usually done by 
combination of the basic thermal analysis technique with a mass spectrometer, or in the gas cell of 
a FTIR spectrometer coupled to the T A module. Important factors when combining or coupling 
different analytical methods for detecting and analysing evolved gases or volatiles are: a) the 
selection of the methods to be combined, b) selection of the coupling method and coupling 
interface, c) the gas flow conditions in the combined instruments, d) detection limits for the evolved 
gases, e) the response time and resolution of the gas analysis system, f) the temperature range and 
type of samples to be analysed, g) correlation between the data acquired from different detector 
systems, h) interpretation of the results, i) and the possibility of calibration and quantitative work 
(33]. 
FTIR. allows the whole IR spectrum (400- 4000 cm-!) to be scanned several times within one 
second [34]. TG-FTIR allows for real-time collection of spectra of gases evolved during sample 
heating, so that one can make assignment of the evolved gases to the detected mass loss [35]. The 
interface for the coupling ofFTIR. to the thermobalance has to transfer the gas flow into the gas 
cell of the spectrometer without pressure changes and losses by condensation and without 
secondary reactions occurring in the transmission line. 
0) Ceramic Nonie 
o Purge Outlet 
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Figure 2.1 The Perkin-Elmer TO furnace system showing the purge outlet that leads 
evolved gases to the gas line. 
The transfer line is usually made of PTPE (polytetrafluroethylene) and is heated so that gases are 
carried through this line to a heated IR gas cell without condensation. Figure 2.1 shows the purge 
outlet which leads to the transfer line [34J. A gas cell (see Figure 2.2) with a long light path 
ensures high sensitivity and good light transmission through the fumes coming from 
decomposing samples. Samples are loaded in the same way as they are loaded in TO and there 
is no need for transfer- line disconnection [33]. 
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Figure 2.2 The Perkin-Elmer on-line gas cell for evolved gas analysis using TG-FTIR 
Factors that should be avoided once the interface has been connected are: loss of gas by 
condensation at cold spots; l~w.detection sensitivity due to heavy dilution with the purge gas; 
low-time and temperature resolution because of long transfer times; mixing of evolved gas by 
diffusion and by uncontrolled flow conditions, and variation in the purge gas composition [33]. 
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FTIR results are usually presented in a Gram-Schmidt plot (a typical example is shown in Figure 
2.3). In a Gram-Schmidt plot, the total IR absorption over a set wavelength-range is plotted 
against time and the plot is comparable, under ideal operating conditions, with the derivative mass-
loss versus time (DTG) plot. The TG heating programme enables the time to be related to the 
temperature. It is necessary to correct for any time-delay that occurs as the evolved gases are 
passed through the transfer line to the gas cell. Berbenni el al. [3 5] stated that the relative rates of 
reaction and of purging determine the spectral response. A three-dimensional stacked plot with 
information about the spectral ranges and the absorbances of the released gases as a function of 
the time, and hence through the heating rate the temperature, at which they are released can also 
be obtained from the TG-FTIR results (see Figure 2.4). 
o 
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Figu re 2.3 A typical Gram-Schmidt plot of total IR absorption over a set wavelength window 
against time, compared with a DTG curve (dashed line), showing the evolution ofHCL CO2 and 
S02 from brick clay as three main peaks [33]. 
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Figure 2.4 Stacked plot for the degradation of polystyrene, showing IR absorbance against 
temperature and time. The peaks correspond to the release of H20 (3600-3400 and 1650-1600 
cm-' ), CO2 (2360-2340 and 750 em") and aromatic hydrocarbons (CH) (3040 and 1600-1580 
em"). The temperature and the time are related through the heating programme [ 34]. 
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2.1.6 Thermomicroscopy (or Hot-Stage Microscopy, HSM) 
This technique involves microscopic examination of the outward appearance ofthe sample during 
a heating programme and can provide evidence of processes such as sintering, decrepitation and 
creeping and foaming of melts that are only really detectable by direct observation [36]. Controlled 
temperature stages for microscopes are readily available and can cover wide temperature ranges 
[32]. These instruments are equipped with standard photographic equipment, or video cameras 
which can record the observations as the events are taking place. 
2,2. Applications of thermal analysis in the study of pharmaceuticals 
2.2.1 General 
Thermal analysis has many applications within the pharmaceutical discipline. These applications 
include morphological studies, melting behaviour, determination of purity, stability in the solid state 
and drug-excipient interactions [37, 38]. Some examples of pharmaceutically important 
information derived from the various thermal analysis techniques [37] are given below: 
Table 2.1 Applications of thermal analysis in the study of pharmaceuticals [37]. 
Processes DSC HSM TG DTA 
Melting points a a na a 
Polymorphic transitions a a a a 
a a a a 
Glass transition a na na a 
Purity determination a pa na pa 
Drug-excipient interaction a pa pa pa 
Decomposition a na a a 
Desolvation a a na a 
key: a-applicable, na- not applicable, pa- potential application. 
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2.2.2 Purity determination 
Use of pure active and inactive ingredients for the preparation of pharmaceutical products is 
essential because undesirable impurities could have serious consequences. The DSC method of 
purity determination is based on the principle that the presence of impurities ( solute) in an organic 
compound (solvent) depresses the melting point and that the degree of impurity for dilute systems 
is described by the van't Hoffequation [39]. The theory only holds true if the following conditions 
are fulfilled : a binary eutectic system is formed, the components are miscible in the liquid state, 
thermodynamic equilibrium is achieved and no decomposition occurs on melting. Even though 
there are these limitations, analysis ofDSC measurements can yield all the information required (0 
determine the purity, the melting point and the heat of fusion ofa substance without the need for 
a pure sample of the substance being tested. 
2.2.3 Processing of solid pharmaceuticals 
Thermal analysis techniques can be used to provide information and understanding of how key 
production parameters and the manufacturing environment may affect the morphology and physical 
properties ofa drug [37]. Temperatures of thermal events such as the glass transition, melting, 
boiling, sublimation, decomposition and isomerisation are obviously important. When hydrates or 
solvates or volatile compounds are involved in the formulation, the loss of water or volatile 
compounds can be followed . A manufacturer needs to ascertain how factors such as concentration, 
stir-rate and reaction temperature affect the crystal habit and the morphology of the material; how 
pressure, temperature and relative humidity affect crystallinity during particle-size reduction, and 
how purity and crystallinity affect the stability ofthe final product. Many drugs under development 
do not reach the market, because their instability can produce degradants with unpredictable side-
effects. Thermal analysis can also be used for identification purposes by simple "fingerprint" -type 
of comparison ofTG and lor DSC curves for the sample with those for known reference samples. 
DSC can also be used to monitor the behaviour of, or identify, polymers used in packaging 
material. For example, the glass transition of amorphous cellulose derivatives can be used to 
identify the film coatings of biodegradable drugs [40] . 
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2.2.4 Drug-excipient interactions 
F or drug/excipient mixtures, any interaction between the drug and the excipient, such as miscibility 
in the melt, could lead to eutectic formation, effectively decreasing the purity of the drug. 
Comparison of the DSC curves of the individual compounds with those of mixtures can reveal 
changes that could be due to interaction in the solid state, such as complex formation or other 
chemical reactions [40J . 
2.2.5 PolymO/phisl11 
The study of polymorphism of drug substances is of great importance. Many drugs exists in 
different crystalline modifications, as well in the amorphous state. These forms all melt to give the 
same liquid phase, but properties such as melting and sublimation temperatures, stability and 
solubility are different. In dosage forms, these differences usually lead to differences in dissolution 
and bioavailability [40]. DSC can be used to detect : a) solid-solid transitions before melting, b) 
melting of the crystalline form and recrystallisation to a second form from the melt which has a 
higher melting point, and c) cases where each crystalline form melts without any transition to the 
other form. 
2.2.6 Atmospheric conditions 
Thermal analysis can also be used to study the effects of atmospheric conditions, such as the 
presence of oxygen and I or water on the stability of drugs, many of which are very susceptible to 
oxidation andlor hydrolysis. [ 41]. 
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Chapter 3 
3. DRUG STABILITY TESTING 
3.1 Introduction 
The stability of a drug [45] can be affected by factors such as the presence of impurities or 
additives, and the container and environment used for storage. Included under environment would 
be the effects of temperature and the presence of oxygen and water or other solvents. Impurities 
or additives may cause discolouration of tablets and, in certain containers, transfer of drug among 
a set of normally equivalent tablets may occur after several months and result in decreased 
uniformity of the contents. Alam and Parrot [42] found a close correspondence between the 
changes occurring in the dissolution rate of hydrochlorothiazide tablets at elevated temperatures 
and those occurring after prolonged storage at room temperature. 
Before marketing of a product, packaging tests and shelf-life determinations are essential to the 
manufacturer, as well as the determination of photostability, so that the storage conditions can be 
specified. Exposure of a drug to light might produce undesirable side-effects such as 
photosensitivity effects, or may bring about loss of therapeutic activity. 
3.2 Accelerated testing 
The effects of storage for long periods at ambient temperatures can be simulated by short periods 
of treatment at elevated temperatures, provided that extrapolation of results is not done over a 
temperature range that includes phase transitions . In long-term stability tests, samples can be stored 
for specified times under specified conditions and analysed at regular intervals . Any changes in the 
product can then be recognized from sample to sample. A more rapid procedure is to investigate 
the kinetics of the decomposition reactions. Such studies may be made under a range of different 
isothermal conditions, as in conventional homogeneous kinetic experiments, or under programmed 
temperature conditions using TG or DSC results obtained at a series of different heating rates. 
Many methods of extracting kinetic information from non-isothermal measurements have been 
proposed [32] . If the kinetic measurements have been made reliably and a valid kinetic analysis 
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was used, the results should allow limited predictions about decomposition behaviour to be made. 
Interpolation of kinetic measurements within the range of experimental parameters used is always 
more reliable than extrapolation outside the range. Extrapolation has to be done with caution 
because of the generally low melting points and the existence of several polymorphic forms of 
drugs, so a single degradation mechanism may not apply. 
3.3 Drug-excipient interactions 
The morphology of an excipient may also play an important role in the stability of the final product 
[43]. The chemical stability of the drug is usually compared with the stability of mixtures of the 
drug with each excipient. Chemical instability is defined as a chemical interaction that causes a 
detrimental change to the material and can lead to a loss of potency. This interaction may also 
result in the formation of potentially harmful degradation products. Degradation can be 
environmentally initiated (e.g. photodegradation, atmospheric oxidation, hydrolysis) [43], or be 
initiated from within the drug formulation by autocatalysis and/or interactions with other excipients 
[44], or impurities associated with the excipients. 
3.4 Solid dosage forms 
Most of this study is concerned with the solid-state stability of FR. Drug stability in the solid state 
is important because solid dosage forms are more common than other forms and the first clinical 
trials are usually carried out on solid dosage forms [45]. When a solid drug is placed in a vacuum 
and exposed to temperatures at which it decomposes at a measurable rate, the following reaction 
types may occur: 
i) Solid -> solid + solid 
ii) Solid -> solid + liquid 
iii) Solid -> liquid + liquid 
iv) Solid -> solid + gas 
v) Solid -> liquid + gas 
vi) Solid -> gas + gas 
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Some of these reaction schemes are theoretically possible but not very likely. Reactions of types 
iv) and v) have been the most investigated reaction schemes in pharmaceutical science. 
3.5 Effects of moisture 
Moisture adsorption plays an important role in the physical and chemical stability of solid dosage 
forms, excipients and polymers for sustained-release formulations [46]. Many drugs are known to 
undergo hydrolysis or oxidation in the presence of moisture, so it is important to study the rate of 
moisture uptake and the equilibrium moisture content (EMC) of solid dosage forms and excipients 
to obtain information useful for choosing excipients such as tablet-disintegrating agents, direct 
compression carriers and binders, and for deciding on the humidity control required during storage 
(46) . Moisture determination is thus part of shelf-life determination. 
The moisture absorbed by drugs and excipients influences the flow, compression characteristics 
and the hardness of granules and tablets [46]. A typical example of a drug whose stability can be 
affected by moisture is aspirin [47]. Even though most of the water is driven off after wet 
granulation, there is still sufficient residual moisture to induce excessive decomposition on 
subsequent storage. Dry granulation methods thus have to be used (i .e. slugging, roller 
compaction). Measurements of moisture transmission through polymer fIlms may be useful for 
characterization of the dissolution and the transport of drugs from their dosage forms (46) . Edgar 
and Swan (48) listed four major factors that affect the rate of moisture absorbed by drug 
substances: a) the water vapour pressure gradient between the atmosphere and the adsorbed 
moisture layer on the drug substance, b) the temperature, c) the surface area of solid drug exposed 
to the water vapour, d) a reaction constant characteristic of the solid [48]. 
Mikulinskii and Rubinshstein (49) studied the kinetics of moisture uptake by MgS04 and concluded 
that the process of moisture uptake is dependent on two steps: a) surface adsorption, occurring at 
a rate proportional to the difference between the partial pressures of the water vapour in the 
atmosphere and that of the saturated salt solution, and b) water diffusion into the crystal, at a rate 
dependent on the product of the diifusion coefficient and water concentration gradient. The 
thickness ofthe layer of the drug substance also influences the water uptake [50]. 
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Studies on moisture uptake by pharmaceutical powders at various relative humidities were done 
by Czetsch-Lindenwald [51] and three classes of hygroscopicity were identified: a) softening 
substances, b) substances retaining moisture, and c) antistatica (disturbance by moisture in the 
environment surrounding the solid material causes the particles to be loosely bound). Carstensen 
et al.[52] emphasised the importance ofperforrning moisture-stress tests of tablets, because when 
gelatin softens it becomes more oxygen-permeable and therefore the stability of the drug will 
decrease. Admirat and Grenier [53] defined the hygroscopicity ofa substance in terms of the 
critical relative humidity (CRH). This is the humidity in equilibrium with a saturated solution of the 
substance. They gave a practical example of the definition of hygroscopicity where, if the CRH 
of drug A was 30 % and drug A was stored below or at 30 % RH (relative humidity), no moisture 
adsorption would take place. However, if drug A was stored at over 30 % RH, moisture would 
be adsorbed and the drug A would be said to be hygroscopic [53]. 
In a solid dosage form, moisture may be bound or unbound. Unbound moisture is available to 
participate in hydrolysis reactions, while bound moisture is similar to water of crystallization and 
is not readily available for hydrolysis. The available moisture may form an adsorbed layer or a 
rubbery phase in which hydrolysis can occur in a dissolved state. 
3.6 Effects of temperature 
The effect of temperature on the stability of solid dosage forms can be complicated when: a) 
humidity is not simultaneously controlled, b) one of the ingredients, either the drug or an excipient, 
has a low melting point, c) one of the ingredients has loosely bound water, and alterations in 
temperature change the degree of binding of the water to the excipient, d) one of the ingredients 
of the dosage form is present as a hydrate or solvate and is capable of giving up this bound solvent 
to an unbound state as a result of temperature changes [54]. 
Temperature is known to affect the solubility of a drug in a solvent layer and temperature changes 
may also alter the availability of solvent. If degradation in solution is rapid, the amount of 
degradation will increase if the amount of solvent available increases with increasing temperature, 
that is if "bound" solvent in the form ofa solvate is released, but degradation may decrease if the 
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higher temperature actually helps drive off the loosely bound water in the tablet, thus decreasing 
the amount of solvent present. Excipients may affect the stability of drugs by: a) acting as surface 
catalysts, b) altering the pH of the moisture layer, and c) undergoing direct chemical reaction with 
the drug [54]. 
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Chapter 4 
4. CYCLODEXTRINS AND DRUG/CYCLODEXTRIN MIXTURES 
4.1 Cyclodextrins (CDs) 
Natural cyclodextrins are produced from starch by the action of cyclodextrin glycosyltransferase 
(CGTase), an enzyme produced by several organisms, Bacillus macerans being the most common, 
to form a mixture of cyclic and acyclic dextrins. The three major cyclodextrins are crystalline 
homogeneous, non-hygroscopic substances, with torus-like macro cycles built up from 
glucopyranose units. Structurally these units consist of 6,7 or 8 (i.e. alpha, beta, and gamma 
respectively) D-glucopyranosyl units connected by alpha-(l ,4) glucosidic linkages. The molecular 
structure of naturally-occurring gamma-cyclodextrin [55] is shown in Figure 4.1. 
The 3-D molecular configuration of these very stable, non-reducing cyclic oligo saccharides takes 
the form of a toroid with the upper (larger) and lower openings of the toroid presenting secondary 
and primary hydroxyl groups, respectively, to the solvent environment (see Figure 4.2). The 
exterior of the toroid is hydrophilic as a result of the electron-rich environment provided, whereas 
the interior is intensely hydrophobic [56]. 
The cyclodextrins are reasonably soluble in water, with beta-cyclodextrin being the least soluble 
(as can be seen from Table 4.1). Szejtli [57] reported that the solubility of beta-cyclodextrin 
increases sharply with temperature and this allows easy crystallization on cooling (see Figure 4.3). 
Pagington [58] , and Brewester et al. [59] have reviewed some of the properties ofcyclodextrins 
which limit their application. These are as follows: 
i) The cyclodextrins are fairly stable in alkaline media, but are susceptible to acid hydrolysis, 
ii) They are hygroscopic, with beta-cyclodextrin being the least hygroscopic and the most stable 
in air. Storage may require containers to be sealed under dry conditions. 
iii) They can be expensive, although recent advances in enzyme technology and in large-scale 
production techniques have lowered their prices. 
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iv) Toxicity has been a problem, for example the use ofbeta-cyclodextrin in parenteral dosage 
administration. Toxicity tests have shown, however, that orally-administered beta-cyclodextrin is 
harmless, without any embryotoxicity or teratogenic effects, 
v) The low aqueous solubility of the most widely used cyclodextrin, beta-cyclodextrin is a major 
limitation in its use. 
vi) In damp conditions, cyclodextrins are subject to bacterial attack. Thymol or phenol can be 
used to prevent bacterial growth and product degradation. 
It was not until the late 1970's that researchers started modifying cyclodextrins with the intention 
of solving the problems of toxicity and aqueous solubility. Pitha [60] looked at the enhanced 
solubilizing effect achieved by modifying each of the natural cyclodextrins with alkyl groups. Since 
that time, cyclodextrins have been modified with many different groups. 
Table 4.1 Physical properties of some of the naturally-occurring cyclodextrins [55, 61] 
Alpha (a) Beta (Jl) Gamma (y) 
molar mass (g mol") 972 1135 1297 
glucose monomers 6 7 8 
internal cavity diameter (A) 4.7-5.3 6.0-6.5 7.5-8.30 
height of toroid (A) 7.9 ± 0.1 7.9 ± 0.1 7.9± 0.1 
outer diameter (A) 14.6 ± 0.4 15.4 ± 0.4 17.5 ± 0.4 
approx. volume of cavity (106 pm') 174 262 427 
water solubility (giIOO ml:25 0C) 14.2 1.85 23 .2 
melting range (0C) 255-260 255-265 240-245 
water of crystallization (mass %) 10.2 13 .2-14.5 8.1-17.7 
water molecules in the cavity 6 11 17 
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Figure 4.1 The molecular structure of naturally-occurring gamma-cyclodextrin [55J 
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Figure 4.2. Illustration of the lower and upper openings of the toroid of a general structure of 
cyc10dextrins where R can be H in case of natural CDs or a substituent in case of modified CDs 
[61J . 
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4.2 Inclusion complexes 
The cyclodextrins have different cavity sizes, so that inclusion complexes can be formed between 
the cyclodextrins and "guest" molecules if the size ofthe guest molecule does not exceed that of 
the internal cavity of the cyclodextrin (i .e."host" molecule) [61] . 
Frank [62] defined an inclusion compound as a unique form of chemical complex in which one 
molecule is enclosed within another molecule or structure of molecules. The combination of the 
"guest" with "host" is characterized by the absence of ordinary chemical bonding. Coetzee [63] 
reported that inclusion or complex formation was dependent on the stereochemistry and polarity 
ofthe molecules involved. The close fit ofthe components involved in complex formation produces 
a combination of significant strength due to complete distribution offorces that are present between 
the interacting compounds [62]. 
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Figure 4.3 Solubility ofbeta-cyclodextrin in water (Szejtli ) [57]. 
Cramer et at. [64] investigated the inclusion compounds formed between azo-dyes and 0.-
cyclodextrin and identified six steps leading to complex formation: 
a) the approach of the guest molecule to the cyclodextrin molecule, 
b) the loss of water from the interior of the cyclodextrin cavity, 
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c) breaking down of the water structure around the portion of the cavity where the guest molecule 
is to be included and the transportation of some of these water molecules into solution, 
d) interaction of the guest molecule substituents with the groups on the rim of the cyclodextrin, 
e) possible formation of hydrogen bonding between the guest molecule and the cyclodextrin, 
f) reconstruction of the water structure around the exposed parts, if any, of the guest molecule after 
inclusion has taken place. 
Inclusion complex formation thus proceeds by an energetically favoured interaction of a relatively 
non-polar guest molecule with an imperfectly solvated hydrophobic cavity. Cyclodextrins are 
stabilized by various intermolecular interactions which include hydrophobic interactions, 
hydrogen-bonding between the guest and host, and Vander Waals forces (both permanent induced 
dipole-dipole interactions and London dispersion forces) [65]. Figure 4.4 gives an illustration of 
the equilibrium binding of a drug (guest) and a cylodextrin (host) to form a complex. 
< + 
--> 
Drug Cyclodextrin 1: 1 Complex 
Figure 4.4 Illustration ofthe equilibrium binding of a drug and a cyclodextrin in inclusion 
complex formation [66]. 
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Hedges [67] mentioned that complexes are easily formed and the most commonly used methods 
for preparation of complexes are coprecipitation, mixing as slurries or pastes (called kneading) as 
well as dry mixing (also known as physical mixing) . Cyclodextrins are known to contain water 
molecules within their cavities and this has been noted to influence complex formation because 
water is often the medium for dissolution of the cyclodextrin and the guest, as well as being the 
driving force for the hydrophobic interaction of the guest with the cavity of the cyclodextrin [67]. 
Les Bas et al.[68] explain how water can assist in the formation ofa complex. Water molecules 
in the cavity of the cyclodextrin molecules can form a bridge between the hydroxyl groups of 
adjacent cyclodextrin molecules to form a cage that assists in trapping the guest inside the cavity 
and thus forming a complex. 
4.3 Some industrial uses of cycJodextrins 
Cyclodextrins have many industrial uses. For example, in the dyeing offabrics [67] the use of 
cyclodextrins [69] enhances the solubility of the dye in water and, hence, more dye goes into the 
fabric, thus decreasing the amount of dye wasted in the effluent. CDs can also increase the 
efficiency of biodegradation of hydrocarbons [70] by increasing their solubility and decreasing their 
toxicity, thus resulting in an increase in microbial and plant growth. 
CDs can also be used to control the viscosity of water-based paints during their manufacturing [68]. 
Thickeners are complexed with cyclodextrins in order to decrease the viscosity thus making mixing 
easy. The desired viscosity can then be restored by addition of other paint components that will 
displace the thickener from the cyc\odextrin cavity. CDs can also remove undesirable components 
selectively from mixtures, for example cholesterol from animal fats [71] and polyphenolic 
compounds, which cause enzymatic browning, from fruit and vegetable juices [72]. CDs also can 
be used in masking or eliminating the irritating or toxic effects of insecticides [73], and generally 
in decreasing volatility, e.g .in the prevention of odour in skin tanning preparations [74] . 
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4.4 Drug / cyclodextrin mixtures 
Because cyclodextrins are able to form inclusion complexes [75] with suitably-sized molecules, the 
inclusion of drug molecules has come to be particularly important. This inclusion process can occur 
in the solid state, as well as from solution. These inclusion complexes can have physical, chemical 
and biological properties that are dramatically different from those of either the parent drug or the 
cyciodextrin. The solubility and dissolution rate of the drug may be increased, while the volatility 
may be decreased. Release rates of the drug may be altered and local irritation effects may be 
modified. A major desirable effect of inclusion is a possible increase in the thermal and or 
photostability of the drug. 
Access of the drug molecule to the cavity of a particular cyclodextrin is determined mainly by the 
molecular geometry of the guest molecule. Inclusion complexes usually form quite rapidly 
(equilibrium may be attained in minutes), because even the most lipophilic compounds are solvated 
by water to some extent. These discrete hydrated molecular particies are better able to get past the 
hydrophilic hydroxyl groups at the entrance to the cyciodextrin cavity. 
The water molecules involved in hydrating the potential guest molecule can interact with the 
hydroxyl groups on the rims of the cydodextrin toroid, or they may simply shield the hydrophobic 
drug molecule from being repelled by the hydroxyl groups. Once past the rim of hydroxyls, the 
hydrating molecules of water are driven from the hydrophobic cavity leaving the naked drug 
molecule to find its most stable position in the cavity. In such a situation, inclusion results in some 
protection against hydrolysis of the drug molecule. For extremely insoluble substances, true 
equilibrium may not be achieved for hours, or even days, because molecular segregation due to 
hydration occurs extremely slowly. 
For enhancement of the photostability of a drug by cyclodextrins, the photosensitive moiety of the 
guest molecule normally has to be located inside the cyciodextrin cavity. Complexation of 
furosemide with cydodextrins has been studied by Ozdemir and Ordu [29]. They reported an 
improvement of the dissolution properties of furosemide by complexation with beta-cydodextrin 
(BCD). 
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4.5 CycIodextrins as excipients 
Excipients are compounds that are used in drug formulation and tableting (i. e. making of the tablet 
pellets). Starch products are widely used in tableting for both their disintegration and binding 
properties [38]. Cyclodextrins thus form a special class of excipients and the possibility always 
exists that drug molecules can be included within the cavities of CD molecules. 
Formulation of a stable, effective dosage form reqUIres careful selection of excipients for 
compatibility [76]. The administration, consistent release and bioavailability of the drug and the 
protection of the active moiety from the environment must be ensured. Fassihi and Persicaner, [77] 
reported that excipients are often assumed to be inert, but chemical and physical interactions 
between drugs and excipients are common. 
Most excipients have appreciably high water contents. Moisture may exert either beneficial or 
adverse effects on the drug. Connors, Amidon and Stella [54] reported that starch with a fairly high 
moisture content, compared with lactose and micro-crystalline cellulose, caused minimal degradation 
of the drug molecule. Excipients can also affect the stability of a drug by: (1) acting as surface 
catalysts; (2) altering the pH of the moisture layer; and (3) undergoing direct chemical reaction with 
the drug. 
Interactions may be desirable or undesirable. Desirable interactions are those that stabilize the drug 
against thermal or photodegradation, and/or improve the solubility of an active ingredient. 
Undesirable interactions are also known as incompatibility and these interactions are those that lead 
to changes in one or more of the components which then bring about loss of activity, or complete 
deactivation of a preparation, or even production of toxic degradants. 
Thermal analysis (Chapter 2) can be used to study interactions between the drug and excipients and 
whether or not the drug is actually being stabilized by the presence of the excipients. 
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4.6 Drug delivery 
For pharmaceutical use, the behaviour of the drug / cyclodextrin complex in the gastrointestinal 
tract is important, because the guest (the drug) has to be absorbed. The dissolution and dissociation 
of an inclusion complex on contact with water (i.e. gastrointestinal fluid) is represented [78] by the 
following equilibria: 
solid inclusion complex ~dissolved inclusion complex - free cyclodextrin + free active ingredient 
The generally hydrophobic, active ingredient is thus presented in a molecular state to the lipoid 
mucosa of the gastrointestinal tract and it is therefore easily absorbed. Absorption would result in 
a displacement of the previous equilibrium with the appearance of new free molecules of the active 
ingredient. The drug absorption process from a solid complex is illustrated in Figure 4.5 [79]. 
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Figure 4.5 Schematic representation showing how the drug is absorbed from the drug-
cyclodextrin complex (solid complex) through biological membranes [79]. 
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4.7 Limitations of furosemide and the objectives of this study 
Furosemide is known to exhibit poor bioavailability and high bioinequivalence due to its low 
aqueous solubility and is also known to be highly light and heat sensitive (as explained in Chapter 
1). Cyclodextrins have been used with great success to increase the solubility of drugs and also to 
increase their stability to light and heat. Thus the objective of this study was the evaluation of the 
extent of interaction between FR and CD' s through examination of kneaded and physical mixtures 
of FR and gamma and beta-cyclodextrin. The thermal and photostabilities of mixtures FR with 
cyclodextrins were also compared with the behaviour of pure furosemide under the same 
conditions. 
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ChapterS 
5. EXPERIMENTAL 
5.1 Materials 
5.1.1 Furosemide 
Furosemide (Tradename: Lasix®) (also known as fiusemide) 
Empirical formula: (S02NH2)·(CI) .C,H2·(COOH).NHCH2·C.H,o 
Molar mass: 330.8 g mol·' 
(molecular fragments) 
% composition 
Melting range 216-222 °C [19] . 
80 35 .5 74 45 29 67 
24.2 10.722.4 13 .6 8.8 20.3 
H 
CI 
I 0 N-CH>f.) 
OOH 
Figure 5.1 Furosemide (FR) 
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5. J.2 Spectroscopic characterization of the furosemide sample 
A sample ofFR was characterized by UV-visible, NMR, IR and mass spectroscopy. 
UV-visible spectroscopy: Samples of furosemide (FR) were dissolved in 0.5 M NaOH solution 
in which it is very soluble. The solution was then examined in the wavelength region of 90-400 
nm. Maxima were obtained at 330.9 nm, 272 .0 nm and 229.3 nm. From the analytical profile of 
furosemide, the UV the spectrum ofFR in 0.1 N NaOH was reported to exhibit several maxima 
wavelength values ranging from 226 nm to 336 run [3]. 
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Figure 5.2 UV-visible spectrum of furosemide in 0.5 M NaOH solution. 
Mass spectroscopy: 1.055 mg of furosemide was dissolved in 10 ml of methanol to make a 
homogeneous solution . . The solution was then injected into the mass spectrometer. A base peak 
was observed at 330 g mol· 1 which is the molar mass of furosemide. The peaks observed in the 
MS spectra represent the molecular fragments of furosemide. The fragment appearing at 81 
g m01·1 is possibly -CH2.C4H30; and the one at 96 g m01-1 could be HNCH2.C4Hp. 
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Figure 5. 3 Mass spectrum of furosemide in methanol solution 
Nuclear magnetic resonance spectroscopy (NMR): Furosemide was dissolved in DMSO-d6. 
Chemical shifts of the protons were consistent with literature values. All the peaks ofFR proton 
spectrum are reported [3 1 to appear as sharp singlets with the following chemical shifts: -CH2 at 
4.56 (ppm), H3 and H4 of the furan ring at 6.416 (ppm), H2 offuran ring at 6 (ppm), H3 of phenyl 
group at 7.326 (ppm) and H6 of phenyl group at 8.42 6 (ppm). 
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Infrared spectroscopy (lR):- Furosemide was mixed with Nujol to form a mull and the sample was 
examined in the region 14000-700 cm-' in transmittance mode_ The functional groups present 
were confirmed by the absorption bands at the wavenumbers shown in Table 5.1 . 
Table 5.1 Infrared absorption bands of furosemide 
Vibrations **Literature [3] values lem-' Experimental values lem-' 
N-H(R2NH) 3350-3400 3500 - 3100 
C=O (COOH) 1671 1668.0 
N-H (NH2) 1596 1455.6 
S=O (symmetric S=O) na (not applicable) 1141.3 
S=O (S02) 1322 1321.4 
C-Cl 582 581.7 
** the FR was run using a KBr-dise 
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Figure 5.4 IR spectrum of furosemide in a Nujol mull 
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5.1.3 Cyclodextrins (CDs) 
Details of the cyclodextrins used in this study are given in Table 5.2. The water contents were 
given by the suppliers. 
Table 5.2 The properties of the cyclodextrins used in this study [55]. 
Cyclodextrin Abbreviation Molar Total water Cavity 
mass/ g mol-l content % by diameter/nm 
mass 
Beta- BCD 1135 14.9 0.8 
Gamma- GCD 1295 11.2 l.0 
The water contents of the cyclodextrins were determined using the Karl Fischer method. 
Approximately 100 mg of the samples was weighed accurately, dissolved in methanol (- 40 ml) 
and then titrated with Hydranal composite (i.e. Karl Fischer reagent). 1 ml of reagent corresponds 
to approximately 5 ml of H20. The percentages obtained (Table 5.3) indicate the total amounts 
of water in each ofthe cyclodextrins, i. e. inside and outside the cavity. 
Thermogravimetric results for samples of beta-cyclodextrin and gamma-cyclodextrin, heated in 
nitrogen at 10°C min- l from 50 to 250°C, are shown in Figure 5.6 and Figure 5.7, respectively. 
Table 5.3 shows the initial mass losses for both BCD and GCD. 
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Table 5.3 Water contents (mass percentages) of the cyclodextrins determined by Karl Fischer 
titration and by thermogravimetry (TG) 
Cyclodextrin Karl Fischer (%) Water TG(%) Water 
molecules per molecules per 
CD molecule CD molecule 
BCD 16 ± 4 12 12.0 9 
(52-120 DC) 
GCD 12 ± 3 9 8.0 6 
(38-126 DC) 
Calculations of the number of water molecules present in the cyclodextrins according to the 
results obtainedfrom the TG (in mass percentage): 
BCD.xH20 where x is the number of water molecules present in BCD 
therefore 18 xl (1135 + 18x) = 121100, (as seen in Table 5.3) 
x = 9, so BCD has 9 water molecules giving BCD.9~O. 
GCD.xH20 , 18x!(l297 + 18x) = 8/100,x = 6 so GCD has 6 water molecules making GCD.6H,o. 
Calculations of the number of water molecules present in the cyclodextrins according to the 
results obtained from the Karl Fischer titrations: 
BCDxH,o where x is the number of water molecules present in BCD 
therefore 18 x /(1135 + 18 x) = 161l00, x = 12, so BCD has 12 water molecules giving 
BCD.12H,o. 
GCDx~O; 18 x 1 (1297 + 18x) = 121100, x = 10, so GCD has 10 water molecules making 
GCD.10H20 
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Figure 5.6 TG curve of BCD heated at 10 DC min· 1 in nitrogen. 
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Figure 5.7 TG ofGCD heated at 10 DC min·1 in nitrogen. 
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The lower percentages of water obtained from TG measurements suggest that not all of the water 
is driven off during heating under these conditions. 
5.2 Preparation of drug/cycIodextrin mixtures 
FRlCD mixtures in the mole ratios 1: 1, 1 :2, 1:3, were prepared as physical mixtures by simple 
mixing of the weighed amounts with a spatula without grinding, or as kneaded mixtures by using 
small amounts of a solvent (in this case ethanol), during the mixing to give a paste, followed by 
drying in air at room temperature. 
5.3 Equipment 
5.3.1 Thermal analysis (TA) 
Thermogravimetry (TG) and differential scanning calorimetry (DSC) were carried out using 
Perkin-EImer Series 7 instruments with Pyris software. Unless otherwise specified, the atmosphere 
was flowing nitrogen and the heating rate was I 0 DC min'l The DSC samples were placed in Al 
pans with lids, but without crimping. The TG samples were placed in open Pt pans. 
The DSC temperature was calibrated using pure indium metal which has a melting point of 156.4 
DC and zinc which melts at 419.5 DC. The enthalpy calibration was based on the enthalpy of 
melting of indium at 28.7 ± 0. 1 J g'l The TG temperature was calibrated using magnetic standards 
of known Curie points, namely nickel at 354°C and perkalloy at 596 DC. 
5.3.2 Thermogravimetry coupled with Fourier transform infrared spectroscopy (TG-FTlR) 
Because TG measures sample mass as a function of temperature, but gives no information on the 
chemical basis of the mass change process, combination with FTIR spectroscopy allows for the 
real-time collection of the spectra of gases evolved during the sample heating and, hence, 
correlation with the observed mass losses. In this study, the Perkin- Elmer Series 7- TG was 
linked to a Perkin-Elmer spectrum 2000 FTIR spectrometer. The PC controlling these instruments 
was equipped with TR-IR software for the System 2000 and 1700-X for the interface. The 
temperatures of the interface and the cell were set to 200 DC to prevent condensation of the 
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evolved gases. The purge gas used was nitrogen and the scan range was 4000-400 em·'. Samples 
were weighed and run using the normal TG procedure and IR spectra were recorded 
simultaneously. 
5.3.3 X-ray powder diffraction (XRD) 
X-ray powder diffraction is an effective method of distinguishing solid phases having different 
crystal structures. Powdered samples were spread evenly on the surface of the sample container 
and then exposed to Cu-Ka. X-rays at goniometer angles from 5 °to 55 0, with a voltage of 40 kY 
and a current of 20 rnA, at a speed of 2 0 per minute. The powder pattern for pure FR is shown 
in Figure 5.6, and is similar to that reported by Ozdemir and Ordu [29]. 
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Figure 5.6 X-ray powder diffraction pattern of pure furosemide (FR) 
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5.4 Photostability testing 
An Atlas SUNTEST CPS+ ( Alta Material Testing Technology B. V, Germany), fitted with a 
xenon lamp and solar ID65 filter was used for irradiation ofthe samples. The samples (i. e. FR and 
FRlCD mixtures) were irradiated at a dose rate of 550 W h m-' for set time periods, with the 
temperature of the instrument kept at 40 DC. The samples (10 mg) were covered in plastic wrap 
and placed in 30 ml clear glass beakers. The samples were spread evenly in the beaker so as to try 
to expose the maximum number of particles to the irradiation. Six samples at a time were placed 
alongside each other for the duration of the irradiation. The ICH recommended conditions are 
exposure for 10 to 12 hours at 200-250 watts h m- 2 So an exposure of about 5 hours at 550 
watts h m-' would be approximately 44 hours at 200-250 watts h m -' . After such an exposure, the 
samples appeared to be unaffected, so even longer exposures were used. 
Dark control samples, covered with aluminium foil , were included in the irradiation process to 
determine whether any thermal decomposition occurred under these conditions. 
5.5 High perfOl-mance liquid chromatography (HPLC) analysis 
An HPLC method [84] was used to determine the amount of drug remaining after irradiation. The 
mobile phase was prepared by measuring volumes of methanol, water and acetic acid accurately 
in the ratio 60:39:1, to give a total volume of250 ml. Samples were prepared as follows : 10 mg 
of furosemide was weighed, dissolved in 2 ml HPLC water and made up to 50 ml using Higher 
Grade HPLC methanol to give a solution of concentration 0.8 mg ml-l which was then diluted to 
0.08 mg ml-l for use in the analysis. 
A 30 cm, 4.6 mm i.d, CIB 10 ~m bondapak column was used. The detector wavelength used was 
254 nm and the flow rate was I ml min-I , with a pressure of 1990 to 2208 psi for the injections. 
20 ~l of the sample was injected and the data were recorded at a chart speed of30 cm h-I with the 
sensitivity of the detector being 0.1 AUFS . 
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Chapter 6 
6. RESULTS OF THE THERMAL STABILITY STUDIES 
6.1 Furosemide (FR) 
A typical DSC curve for furosemide heated at 10 DC min-1 in N2 (Figure 6.1, curve B) shows a 
small endotherm (about 2 J g-l) with onset at about 138 DC, followed by an endotherm at about 222 
DC (melting) which is immediately swamped by a large exotherm (-107 J g-l) (decomposition) . c.H 
values are very dependent upon the baseline choice. Other estimates of t.H for the exotherm were 
-94 and -100 J g-l . 
The TG curve for FR at 10 DC min-1 in N2 (Figure 6.1 , curve A) shows a two-step mass loss, with 
the first mass loss having an onset at about 208 DC, which then accelerates until about 218 DC. 
The second step follows immediately, from about 2 18 DC to 247 DC. The mass loss for the first 
step was about 2 % and the temperature range corresponds closely with the melting endotherm 
followed by exothermic decomposition seen in the DSC curve. 
The mass loss for the second step is acceleratory and is far from complete at 280 °C (IO %). The 
temperature range is extended to 650 DC in Figure 6.4. Decomposition is still incomplete (about 
30 % mass loss) at this high temperature and the rate of mass loss is approximately constant at 
about I % per minute. 
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A) TG curve of Furosemide (FR) 
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Figure 6.1 TG (curve A) and DSC (curve B) results for FR heated at 10 °C min-! in nitrogen, 
showing the melting ofFR accompanied by rapid exothermic decomposition. 
To test for reversibility ofthe small endotherm with onset of about 138 °C, a sample of furosemide 
was weighed and then heated in the DSC from 50 -180°C at 10°C min-! . The sample was cooled 
and then heated again from 50-180 °C at 10°C min-! (Figure 6.2). After heating, the sample 
retained its white colour and there was no mass loss. The endotherm was clearly visible in the 
repeated scan, indicating that the process is readily reversible. 
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Figure 6.2 DSC curves for furosemide showing the reversibility of the small endotherm with the 
onset at about 13 8 DC, after initial heating to 180 DC, followed by cooling and reheating the 
sample. 
TG-FTIR was used to determine the gaseous decomposition products formed on heating FR. 
From the molecular structure of FR. COl and SOl were considered to be possible gaseous 
products so the appropriate spectral regions [34]. namely 2100-2600 em" for COl and 1150-135 
cm " for SOl. were selected for examination. Other possibilities for gaseous decomposition 
products ofFR are HCI and NH3 No convincing evidence for these gases was found in the region 
of3059-2650 cm" for HCl and 986-931 cm" for NH3. A stacked plot ofFTIR spectra obtained 
during a TG run (Figure 6.3) on FR from 0.00 to 60.0 minutes (50 to 650 DC at 10 DC min") is 
shown in Figure 6.4(a). The changes in absorbance in the regions characteristic of CO2 and SOl 
are evident. 
51 
The Gram-Schmidt curves (i ,e. total IR absorption against time curves) of CO2 and S02 (see 
Figure 6.4(b)) showed that both these gases were initially released simultaneously for up to 30 
minutes (350°C), The evolution of S02 then decreased slowly while the evolution of CO2 
increased and was still being evolved at 650°C, At this temperature (650°C), the overall mass-
loss of the drug is seen to be about 71 % but is still incomplete. 
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Figure 6.3 TG and DTG curves for furosemide heated at 10 °C min'\ in nitrogen, The FTIR results 
shown in Figure 6.4 were obtained during this experiment. 
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Figure 6.4( a) Stacked plot of FTIR spectra for furosemide from 0.00 to 60.00 minutes heated 
from 50 to 650 DC at loDe min- l showing the release of CO2 and S02' 
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Figure 6.4(b) Gram-Schmidt curves of the IR absorption of gases evolved on heating 
furosemide from 50 to 650 °C at 10 °C min-! in nitrogen. 
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6.2 Cyclodextrins (CDs) 
6.2.1 Beta-cyclodextrin (BCD) 
BCD, on heating at 10°C min·1 in air is reported [55] to lose water (about 14 %) up to 100°C. 
There is an endotherm at about 220 °c associated with a reversible transition. Thermal 
decomposition (or oxidation in air) starts at 250°C. An endotherm (melting) occurs near 300 °c. 
Ignition occurs at above 300°C in air. 
The DSC curve of beta-cyclodextrin (BCD) heated from 50-350°C at 10°C min· 1 in nitrogen, 
(Figure 6.5, curve B) showed a large endotherm 60-120 °C (AH = 223 J g.l). There is a small 
exotherm (transition) at about 220°C and degradation (overlapping endo-and exothermic events) 
occurs above 300°C. 
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Figure 6.5 DSC (curve B) and TO (curve A) results for beta-cyclodextrin (BCD) heated at 10°C 
min' 1 in nitrogen. 
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The TG curve (Figure 6.5, curve A) shows a gradual mass loss in a single stage between 52 and 
120 °C. The overall mass-loss is 12 %. The temperature range corresponds with the endotherm 
observed in the DSC curve for BCD. This process is attributed to removal of water from the 
cyclodextrin. 
6.2.2 Gamma-cyclodextrin (GCD) 
The DSC curve (Figure 6.6, curve B) for gamma-cyclodextrin (GCD) heated from 50 to 280°C 
at 10 °C min' l in nitrogen, showed a broad endotherm from 50 to 100 °C (Ll.H = 62 J g.I). The TG 
curve (Figure 6.6, curve A) shows a mass loss of about 8 % between 38 and 115°C. Again this 
is attributed to removal of water from the cyclodextrin. 
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Figure 6.6 DSC (curve B) and TG (curve A) results for GCD heated at 10°C min'l in nitrogen. 
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6.2.3 Comparison of the thermal behaviour of BCD and GCD 
The thermal behaviour of the cyclodextrins used is summarized in Table 6.1 
Table 6.1 Thermal behaviour of the cyclodextrins used 
Cyclodextrins Molar TGmass Moles Dehydration: AID Temp 
mass/g mol-' loss % H2O J g" kJ (mol CD)"' range 
1°C 
BCD 1135 12 9 223 253 50 -
120 
GCD 1295 8 6 62 80 40 -
100 
From the temperature ranges, mass losses and enthalpy values in Table 6.1, it can be seen that 
water is much less strongly bound in GCD than in BCD. The enthalpies of dehydration, per mole 
of water removed, are 13.8 kJfor GCD and 33.3 kJfor BCD. Bilal et al. [81] studied the thermal 
decomposition of the BCD-water complex. The BCD used contained 14 % H20 by mass. They 
determined (using solution calorimetry) that to remove one mole of H20 from one mole of BCD 
required MI = 10.50 kJ per mol of anhydrous BCD. 
BCD.nHP (s) ...... BCD. (n-l) H20 (s) + HP (I) 
The tlH value obtained from DSC was 385 J (g BCD),' or 50.2 kJ (mol HP)" . 
BCD. n HP (s) ...... BCD. (n- l) H2O (s) + HP (g) 
The difference 50.2-10.5 kJ is 39.7 kJ is close to the enthalpy of vaporization of water at 100°C 
= 40.6 kJ mol·1 No definite hydrate of BCD exists and the maximum water content depends upon 
the temperature and the water-vapour pressure. At 29 ± 1 °C the number of water molecules per 
BCD is 10 to 12 [83]. 
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6.3 FRI cyclodextrin mixtures 
6.3.1 Mixtures of FR and BCD 
DSC curves (Figure 6.7) of FRlBCD physical mixtures, with various molar ratios, heated from 
50 to 250 DC at 10 DC min-' in nitrogen, showed the dehydration endotherm from BCD at 55 to 110 
DC. The FR transition at 138 DC is visible, as are some of the other features of the FR trace 
between 220 and 230 DC. These events obscure the small exotherm seen in the BCD curve at 
about 220 Dc. Attempts were made to use any changes in the enthalpy values as a measure of the 
extent of any complexation (see Table 6.2). The DSC curves for the kneaded FRlBCD mixtures 
are shown in Figure 6.8. 
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Table 6.2 DSC results for mixtures offurosemide (FR) and BCD heated at 10°C min-' in nitrogen. 
FRlBCD ratio FRmeIting small endo BCD Expected AB 
(216-223°C) (138°C) dehydration for BCD 
AB /J (gFR)"' AB/J (g FR)"' (60-100 0c) AID contribution 
J (g BCD)"' 
BCD only 0 0 223 
-
FR only 14.6 2 0 
-
physical 
mixtures 
1:1 FRlBCD 14.4 1.3 171 173 
1:2 FRlBCD 3.9 0.6 146 195 
1:3 FRlBCD 5.4 Virtually 172 203 
eliminated 
1:4 FRlBCD 0.5 3.1 176 208 
2:1 FRlBCD 7 2.4 112 141 
3:1 FRlBCD 11.3 1.2 105 119 
kneaded 
mixtures 
1:1 FRlBCD 30 1 169 173 
1:2FRlBCD 7.1 2 .2 190 195 
1:3 FRlBCD 1.8 Virtually 195 203 
eliminated 
1:4 FRlBCD 2.5 Virtually 190 208 
eliminated 
2:1 FRlBCD 1.5 2 103 141 
3:1 FRlBCD 15.1 2 .7 113 119 
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DSC results for the physical and kneaded mixtures are not very different. The dehydration 
endothenn of BCD is not greatly affected by mixing, which suggests that water is not displaced 
from the BCD cavity during mixing and hence inclusion of significant amounts of the drug is not 
likely. The complex melting/ decomposition process of FR is, however, altered by the presence 
of BCD. It is of interest that the small endotherm shown by BCD at about 220°C is very close to 
the melting of FR and this may enhance an interaction other than inclusion. Because the DSC 
results indicated little, ifany, interaction between FR and BCD, TO curves were only recorded for 
lhe kneaded mixtures (see Table 6.3 and Figure 6.9). 
'" ,oo ~~~~~--~----~~~--~~~~~~--------------~ 
1:3 FRlBCD phy. mIxture 
" 
10 
Figure 6.9 TO curves of 1:3 FRlBCD physical and kneaded mixtures heated at 10°C min" In 
nitrogen 
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Table 6.3 TG results for the kneaded mixtures ofFR and BCD heated at 10'C min-l in nitrogen. 
FRlBCD molar ratios 1 ,( mass loss % expected values ZO" mass loss 0/. 
{30 - 90)'C for BCD % (209 - 280 ) 'c 
(30-90) ·C 
BCD only 12 12 0 
FR only 0 0 - 14.0 
1:1 FRlBCD 11.5 9.3 20.2 
1:2FRlBCD 10.0 10.5 24.4 
1:3 FRlBCD 9.0 10.9 20.8 
1:4 FRlBCD 6.5 11.2 22.0 
2:1 FRlBCD 5.3 7.6 12.6 
3:1 FRlBCD 13.1 6.4 21.1 
The first mass loss is due to the dehydration taking place in BCD . . The second mass loss is due to 
the degradation offurosemide which is accompanied by melting, as shown by the temperature range 
where this o(;curs aud comparison with the DSC result>. 
15.3.2 Mixtures of FR. and GeD 
Figure 6.10 shows the DSC curves of physical mixtures ofFR and GCD heated at 10°C min-l in 
nitrogen. An endotherm in the range 50-100 'c, corresponding to the dehydration of GCD, the 
weak FR transition around 138°C and the FR exotherm around 220°C were visible. The last two 
curves at the extremes of the mixing ratios are of greatest interest. In the 1:3 FRlGCD mixture, 
the melting/decomposition ofFR appears to be suppressed. The dehydration endotherm of GCD 
is still clearly evident.· For the 2:1 FRlGCD mixture, in spite of the increase proportion ofFR, the 
melting/decomposition is very much suppressed and the dehydration endotherm of GCD has 
virtually disappeared . 
The DSC curvesfoi"kneaded mixtures ofFRlGCD, shown in Figure 6.11, support and strengthen 
the above observations. Kneading has increased the interaction between FR and GCD, as shown 
by the DSC results for the physical and kneaded mixtures ofFRlGCD which are summarized in 
Table G.4. Figure 6.12 shows the TG curves ofFRlGCD mixtures. 
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Table 6.4 DSC results for mixtures ofFR and GCD heated at 10°C min-I in nitrogen 
FRlGCD GCD dehydration Expected Ll.H FR melting range in 
molar ratio (60-100 0c) of dehydration for FRlGCD mixture 
Ll.HlJ(g GCDt' GCD 
GCDonly 62 - 0 
FR only 0 - 216-226 
physical 
mixtures 
1:1 FRlGCD 56 49.4 220-223 
1:2FRlGCD 58 55 220-223 
1:3 FRlGCD 62 57.2 219-223 
2:1 FRlGCD virtually eliminated 41 223-226 
kneaded 
mixtures 
1:1 FRlGCD (30 + 53) = 88 49.5 222-225 
12FR1GCD 52 55 223-227 
13 FRlGCD virtually eliminated 57.2 237-255 
2:1 FRlGCD virtually eliminated 41 217-219 
6.3.3 Comparison of the results for mixing of FR with BCD and GCD 
The DSC results described above suggest that the interaction between FR and GCD is greater than 
between FR and BCD. One of the pointers to this interaction is the change in Ll.H for dehydration 
of the CD component of the mixture which could be an indication of replacement of water in the 
CD cavity by FR These changes in LI.H values for mixtures of FR with BCD and GCD are 
summarized in Table 6.5. 
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Table 6.5 Effect of mixing on the dehydration enthalpies (J (g CD)-I) of the cyclodextrins 
FRIeD ratio BCD L\H dehydration GCD L\H dehydration 
Pure 0 0 
BCD 223 0 
GCD 0 62 
1:1 169 30 + 53 = 88 
1:2 190 52 
1:3 195 virtually eliminated 
6.3.4 The effect of the kneading solvent on FR and on the cyclodextrins 
Because of the quite marked effects found for kneaded mixtures ofFR and GCD in particular, the 
possible effects of the kneading process, carried out separately on the drug and on the cyclodextrins, 
were examined. Samples of the cyclodextrins were mixed in ethanol and treated in the same way 
as the kneaded samples were prepared, except that no FR was present. A sample ofFR treated in 
ethanol was also dried in an oven for one hour at 30°C. These samples were then heated in the 
DSC under the same conditions as for the mixtures, i.e. at 10 °C min-I with nitrogen as a purge at 
20 ml min-I. Results are given in Table 6.6. 
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Table 6.6 DSC results for the solvent-treated cyclodextrins and furosemide 
Cyclodextrins All dehydration T range (0C) AH dehydration T range (DC) 
(after ethanol (untreated) (J go!) J go! 
treatment) (J go!) 
BCD 112 56-105 223 65-112 
GCD 74 58-13 I 62 60-95 
FR AH melting T range (0C) AH melt T range (0C) 
(after ethanol (untreated)(J go!) J go! 
treatment) 
(J go!) 
FR small endo I 137-138 2 137-138 
FR melting 16 201-205 14.4 216-226 
endo 
From the results obtained, it appears that the kneading solvent may replace some of the water from 
the cavity of the cyclodextrins. The melting temperature of the drug treated with the solvent is 
lowered. The effect of the solvent, and hence of the kneading process, could be to increase the 
complexity of the competition between the guest molecule (in this case furosemide) and water and 
ethanol for space in the cyclodextrin cavity. 
6.3.5 Effect of ageing of mixtures 
Because the 1: 3 FRJGCD kneaded mixture showed the most pronounced changes from the physical 
mixture, it was chosen for studying any effects of ageing. A DSC run on the 1: 3 FRJGCD kneaded 
mixture was done a month after it had been prepared. The sample was kept in a cupboard in a 
capped sample vial wrapped with aluminum foil to prevent exposure to sunlight. The results 
(Figure 6.14) showed two overlapping endotherms instead of one dehydration endotherm for the 
cydodextrin. The first endotherm appeared at about (59-73) °c and the second at (74-97) °C. The 
overall Mi value was about 152 J go' . The features ofFR were not visible in either curve. These 
results suggest that the mixture may have adsorbed additional water from the atmosphere. 
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Figure 6.14 DSC curves of 1:3 FRJGCD kneaded mixtures A) fresh sample B) aged ( 1 month) 
sample heated at 10°C min-' in nitrogen. 
6.4 Infrared spectroscopy of FR /cyclodextrin mixtures 
6.4.1 FRlBCD mixtures 
Thermal analysis results suggest that there may be some inclusion ofFR in the BCD cavity. Some 
changes were observed in the IR spectra of the kneaded mixtures, where the N-H stretching band 
at 3274-3336 cm" decreased in intensity and the major characteristic ofFR, the carbonyl stretch 
(C=O) at about 1668.0 em- ', was observed at 1660.9 cm" and was weak and broad. The other 
characteristic vibrations of furosemide were stilI observed, bilt most of them were weak, with the 
C-CI stretch showing at 572.2 cm-' instead of 581.7 cm-', (see Table 6.7). Interactions between 
guests and eyclodextrins in the solid state are known to cause shifts in the IR absorptions spectra. 
Inclusion of drug in the cyclodextrin cavity can lead to changes in bond strengths and henee shifts 
and / or changes in intensity in absorption bands [82). 
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Table 6.7 Infrared absorption maxima for FRlBCD mixtures 
Samples v(C=O)/cm-1 v(CN-H)/em-1 v(S02N-H)/em-1 v(S=O)/cm-1 v( C-CI)/ em- l 
Furosemide 1668 3348 .9 1321.4 1141.3 581.7 
l:lFRIBC 1660 3692 .9 1458 1321 575 .2 
Dphy. 
1:1 no change no change no change no change no change 
FRlBCD 
1m. 
1:2 no change weak band no change no change no change 
FRlBCD 
phy. 
1:2 decrease in weak band weak band no change no change 
FRlBCD band intensity 
1m. 
1:3 broad and weak band weak band no change 575 .2 
FRlBCD intense band 
phy. 
1:3 weak and less disappeared disappeared weak 575 .2 
FRlBCD intense 
1m. 
6.4.2 FRlGCD mixtures 
Water absorption bands were seen in the region (3600-3300) cm-! for all the cyclodextrins. The 
spectrum of the 1:3 FRlGCD kneaded mixture shows some noticeable changes in the characteristic 
band for FR. The N-H stretching band in the region of3500 cm- l had disappeared and the NH2 band 
had decreased in intensity. The C=O vibration band from the COOH group had also decreased in 
intensity. This could be due to hydrogen bonding taking place inside or outside the cavity with the 
strength of the C=O thus decreasing the leading to the decrease in the intensity of the absorption 
band. The C-Cl band had virtually disappeared. Results are summarized in Table 6.8. 
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Table 6.8 Infrared absorption maxima for FRlGCD mixtures 
Samples v(C=O)/cm-' v(CN-H)/cm-' v(SO,N-H)/cm-' v(S=O)!cm-' I'(C-CI)/cm-' 
Furosemide 1668 3348.9 1321.4 1141.3 581.7 
1:IFRlGCD 1668 3285-3338 1560-1595 1316 579 
phy. 
1:1 no change no change no change no change no change 
FRlGCD 
kn. 
1:2 decrease in weak band no change no change no change 
FRlGCD intensity 
phy_ 
1:2 decrease in weak band no change no change no change 
FRlGCD band 
kn. 
intensity 
1:3 broad and disappeared decrease in no change decrease in 
FRlGCD less intense intensity intensity 
phy. 
1:3 disappeared disappeared disappeared disappeared decrease in 
FRlGCD intensity 
kn. 
Thermal analysis results for the 1:3 FRlGCD mixture (kneaded) suggested that some inclusion 
could be occuning. The IR spectra of these mixtures showed some noticeable differences from the 
rest of the mixtures. Firstly, the N-H stretching band in the region of3500 cm-l had disappeared. 
Secondly, the characteristic carbonyl band from COOH had also decreased in size relative to all the 
other mixtures. Thirdly, the NH2 absorption band, which is also characteristic of furosemide, had 
also decreased significantly. Finally, the C-CI band is very weak or absent. In the furosemide 
spectrum it appeared at 581 cm- l [20], but in all the spectra ofthe mixtures it appeared around 571 
cm-I . A shift in the C-CI vibration is indicative of an interaction taking place between the 
cyclodextrin and FR which is most probably due to hydrogen-bonding. 
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6.5 X-ray powder diffraction patterns of mixtures of FR with the CDs 
6.5.1 FRJBCD mixtures 
The XRD powder patterns of pure FR and pure BCD are shown in Figure 6.15 (a) and (b). These 
patterns indicate crystalline compounds. The maximum diffraction intensity of FR occurs at 28 
= 35 'and of BCD at 28 = 15 '. The diffraction pattern ofa 1:3 FRlBCD physical mixture (Figure 
6.15 (c)) is mainly a superimposition of the patterns of the individual components. The pattern of 
the 1:3 FRlBCD kneaded mixture (Figure 6.15 (d)) is very different with some crystallinity and 
a diffraction maxima at 28 = 45 '. 
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PUre BCD 
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Angleldeg Angle/deg. 
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55 5 15 25 35 45 Angle/deg 
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Figure 6.15 X-ray powder diffraction patterns of a) furosemide (FR) b) beta-cyclodextrin (BCD) 
c) 1:3 FRJBCD physical mixture and d) 1:3 FRJBCD kneaded mixture. 
These results support the formation of an inclusion compound under the kneading conditions. 
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6.5.2 FRlGCD mixtures 
TheXRD powder patterns of pure FR and pure GCD are shown in Figure 6.16 (a) and (b). These 
patterns indicate crystalline compounds. The maximum diffraction intensity of FR occurs at 28 
= 35 ° and of GCD at 28 = 45 0. The diffraction pattern of a l:3 FRlGCD physical mixture (Figure 
6.16 (e)) shows not simply a superimposition of patterns of the components, but absence ofthe 
major lines of FR. This trend is carried further in the pattern of the 1:3 FRlGCD kneaded mixture 
(Figure 6.16 (d)) where a strong low angle (28 =7 0) peak has developed. 
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Figure 6.16 X-ray powder diffraction patterns of a) furosemide (FR), b) garnma-cyc1odextrin 
(GCD), e) l:3 FRlGCD physical mixture and d)l:3 FRlGCD kneaded mixture. 
There results support the occurrence of significant interaction between FR and GCD even without 
kneading. 
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Chapter 7 
7. RESULTS OF THE PHOTOSTABILITY STUDIES 
7.1 Irradiation and HPLC analysis 
Powder samples ofthe pure drug and of mixtures of the drug with cyclodextrins were irradiated 
at a dose rate of 550 W h m-2, under the conditions described in detail in Section 5.4. After 
irradiation, samples were analysed using HPLC as described in Section 5.5. The results of 
analyses after various times of irradiation up to 24 hours are given in Table 7.1, and illustrated 
in Figure 7.1. 
Table 7.1 HPLC analysis ofl0 mg samples of furosemide after being irradiated for various times 
at 550 W hlm2 (ho is the peak height for the pure drug.) 
Exposure Peak heightlho % Drug remaining 
time/hrs of FR 
0 16.2116.2 100 
8 15.6116.2 96.3 
12 15.3/ 16.2 94.4 
116.7118 .8 
9.211 2.3 
1
88
.
8 
74.8 
The colour of the sample changes from white to cream during the exposure period. 
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Figure 7.1 Photodegradation ofFR after various times of irradiation at 550 W h m·2 
From Table 7.1 it can be seen that the changes in furosemide after up to 12 hours of exposure 
under the experimental light conditions small. The colour of the powder changed from white to 
cream. To increase the extent of degradation, the time of irradiation of the sample was increased 
to 16 hours and mixtures of furosemide and the cyclodextrins were also irradiated. The exposure 
recommended for accelerated photostability testing by the ICH corresponds to the minimum 
irradiance level of 1.2 million lux hours (21.8 hours SUNTEST exposure at 250 W h m·2 ) referred 
to the visible wavelength range from approximately 400 nm to 800 nm, using a photometric unit 
with the spectral sensitivity ofthe human eye. 
Physical and kneaded mixtures ofFR and BCD and ofFR and GCD, that had been prepared as 
described in Section 6.3, were irradiated under similar conditions to those used for the irradiation 
of pure FR. Dark control samples were also included in the SUNTEST cabinet. All samples were 
analysed using the HPLC method used for pure FR and described in Section 5.5. The results for 
the mixtures are shown in Tables 7.2 and 7.3 and Figures 7.2 and 7.3. 
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Table 7.2 Results of 16 hours irradiation ofFR and ofFRJBCD mixtures at 550 W h m-2 
Sample HPLC peak height/em % FR remaining 
FR (0 h) 18.8 100 
FR(16h) 16.7 89.0 
1: 1 FRlBCD physical 11 .9 63.3 
1: 1 FRlBCD kneaded 10.7 57.0 
1:2 FRJBCD physical 13.4 71.3 
1:2 FRlBCD kneaded 10 53 .2 
1: 3 FRlBCD physical 11.2 59.6 
1:3 FRlBCD kneaded 14.8 78 .7 
Dark control (8 h) 16.0/16.2 98.8 
1 Dark control (12 h) 11601162 198.8 
1 Dark control (16 h) 116.1116.2 198.7 
These results are illustrated in Figure 7.2. There is a general destabilizing effect due to the 
presence of BCD but no consistent trend with composition or with pretreatment of the mixture. 
The colour of all irradiated samples had changed from white to cream, while the dark control 
samples remained white. 
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Figure 7.2 Photodegradation ofFR and FRlBCD mixtures after irradiation for 16 h at 550 W h 
m-'. The molar ratios of the mixtures are shown and p = physical mixture and k = kneaded 
mixture. 
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Table 7.3 Results of 16 hours irradiation ofFR and FRJGCD mixtures at 550 W h m·2 
Sample HPLC peak height/em % FR remaining 
FR (0 h) 16.6 0 
FR ( 16h) 14.9 10.5 
1: 1 FRJGCD physical 12.3 25 .9 
1: 1 FRJGCD kneaded 11.9 28.1 
1:2 FRJGCD physical 12.5 24.1 
1:2 FRJGCD kneaded 10.1 39.7 
1:3 FRJGCD physical 10.9 34.3 
1:3 FRJGCD kneaded 7.2 57.8 
Dark control (8 h) 16.0/162 98.8 
1 Dark control (12 h) 116.01162 198.8 
1 Dark control (16 h) 116.11162 198.7 
The photodegradation ofFRJGCD mixtures is illustrated in Figure 7.3. The destabilizing effect 
due to the presence of the cyclodextrin is again considerable. The kneaded mixtures are more 
susceptible to photodegradation than the physical mixtures and the greater the proportion ofGCD, 
the more extensive the degradation. It is of interest that the 1:3 FRJGCD kneaded mixture 
showed improved thermal stability (see Section 6.3.2) but the same mixture shows decreased 
photostability. This is discussed further in Section 7.4. The colour changes from white to cream 
on irradiation were similar to those for the FRlBCD mixtures except for the irradiated 1:3 
FRJGCD mixture where the colour decreased to yellow (physical) and orange (kneaded). 
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Figure 7.3 Photo degradation ofFR and FRJGCD mixtures after irradiation for 16 h at 550 W h 
m -2 The molar ratios of the mixtures are shown and p = physical mixture and k = kneaded 
mixture. 
To check on the reliability of the HPLC analyses the percentage of FR recovered from the 
mixtures, with the irradiation steps omitted, are given in Table 7.4. These results show that the 
recovery is virtually complete, particularly in relation to the very much larger changes produced 
by irradiation. 
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Table 7.4 The extent of recovery ofFR from FRlCD mixtures for comparison with analyses of 
the irradiated mixtures (see Tables 7.2 and 7.3) 
Samples Peak height/em % FR recovered 
FR standard 17.6 100 
1: 1 FRlBCD phy. 17.4 98.9 
l:l FRlBCD kn. 17.2 97.7 
1:2 FRlBCD phy. 16.9 96 
1:2 FRlBCD kn. 17.3 98.3 
1:3 FRlBCD phy. 17.2 97.7 
1:3 FRlBCD kn. 17.2 97.7 
l:l FRlGCD phy. 17 96.6 
l:l FRlGCD kn. 17.3 98.3 
1:2 FRlGCD phy. 17.5 99.4 
1:2 FRlGCD kn. 17.2 98.7 
1:3 FRlGCD phy. 17.6 100 
1:3 FRlGCD kn. 17.1 97.2 
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7.2 Thermal behaviour of irradiated FR 
7.2.1 DSC and TG 
Samples ofFR were irradiated for 16 hours as described in Section 5.3.2. DSC and TO were 
used to compare the behaviour of the irradiated samples with that of the original sample. 
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Figure 7.4 DSC curves for pure FR and samples ofFR irradiated for various times heated at 10 
DC min'\ in nitrogen. (Note: baselines are arbitrarily shifted vertically for ease of comparison). 
From the DSC curves shown in Figure 7.4, it can be seen that the characteristic features of the 
curve for pure FR, namely the small endotherm at about 138 DC and the melting at 222 DC 
followed immediately by exothermic decomposition, are affected by irradiation and that the 
effects increase with radiation dose. The small endotherm remains visible (t-H about 2 J g'\) but 
onset shifts slightly to lower temperatures with radiation dose. 
81 
After 8 h irradiation, the melting endotherm is absent, the exotherm has broadened slightly and 
the onset has shifted to lower temperature (207°C). After 12 h irradiation the broadening has 
increased and the onset temperature is lower (200°C). After 16 h irradiation, HPLC results 
(Table 7.2) indicate about II % (by mass) degradation ofFR and the exotherm has sharpened 
somewhat (onset 196 °C). The LliI values of the exotherms were not significantly changed (see 
Table 7.5) . The DSC curves of samples used as dark controls showed no changes from that of 
the original FR. 
Table 7.5 Effects of irradiation dose at 550 W hmo' on the thermal behaviour ofFR. 
Dose / h Onset T of exotherm / "C AH /J got 
0 224 -107 
8 207 -95 
12 200 -90 
16 196 -96 
The TG curves for FR and samples ofFR irradiated for various times (corresponding to the DSC 
curves shown in Figure 7.4) are shown in Figure 7.5. The onset temperature of the mass loss 
associated with exothermic decomposition at above 220°C decreases slightly with radiation dose, 
but the extent of the initial step (about 2 % ) is not significantly altered. 
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Figure 7.5 TG curves of pure FR and FR samples irradiated for various time, heated at 10 DC 
min-' in nitrogen. 
A major conclusion from these results is that the photodegradants formed in the solid drug result 
in a product that has decreased thermal stability. The onset temperature of exothermic 
decomposition is decreased by about 30 DC after 16 h irradiation under the conditions described. 
This effect could be an autocatalytic affect of the photodegradants on the solid-state 
decomposition ofFR, or it could be that the degradants lower the melting temperature ofFR and 
hence the onset of decomposition of the molten FR. 
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7,2,2 1'(J-~1'JlI 
The TG and the DTG curves of the samples of the original and irradiated FR, heated at 10 DC in 
nitrogen, are shown in Figure 7.6. Differences are relatively slight 
TG-FTIR was used to determine the gaseous decomposition products formed on heating samples 
ofFR that had been irradiated for 16 hours at 550 W h m,2, Because the only gaseous products 
that were observed on heating unirradiated FR were CO2 and S02 in the spectral regions of2600-
2100 cm,I(C02) and 1350-1150 em') (S02)' the same regions were selected for the irradiated drug 
(16 h), with the possibility of a Iso observing the release ofRCI and lor NH3 in the spectral regions 
00059-2650 cm,l and 931 -986 em'), Figure 7.7 (a) shows the stacked plot ofFTIR spectra 
obtained during the TG run , The Gram-Schmidt curves (i. e, the total IR absorption against time 
curves) ofFR irradiated for 16 h (see Figure 7.7 (b) showed the evolution of CO2 and S02' The 
TG-FTIR results for irradiated FR (16 h) gave no indication of the release ofRCI and lor NH3, 
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Figure 7.6 Comparison of the TO and DTO curves of samples of pure FR with those of FR 
irradiated for 16 h at 550 W h m-2 heated at 10 °C min" in nitrogen. 
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Figure 7.7(a) Stacked plot ofFTIR. spectra for FR irradiated for 16 h 550 W h m·2 heated at 
10 DC min'! in nitrogen from 0.00 to 60.00 minutes showing the release of CO2 
and S02' 
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Figure 7.7 (b) Gram-Schmidt curves of the IR absorption of gases evolved on heating FR 
irradiated for 16 h at 550 W hmo' heated at 10°C mino' in nitrogeno 
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7.3 XRD powder pattern of irradiated FR 
XRD powder patterns were recorded for samples of the original FR and that which had been 
irradiated for 16 hours. The results are shown in Figure 7.8. 
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Figure 7.8 XRD powder patterns of pure FR and of FR irradiated for 16 h at 550W h m'2. 
The XRD powder patterns of the irradiated (16 h) and original FRare considerably different. The 
intense peak observed around 28 = 35 'in pure FR is not present in the pattern of the irradiated 
FR (16 hours). The approximately 11 % of photo de grad ants formed is thus sufficient to disrupt 
the FR crystal structure. 
7.4 Thermal behaviour of irradiated FRJeD mixtures 
7.4.1 FRlBCD mixtures 
The thermal behaviour of both physical and kneaded mixtures ofFRlBCD after irradiation for 16 
h at 550 W h m,2 was examined. The DSC curves for the physical mixtures are illustrated in 
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Figure 7.9 and for the kneaded mixtures in Figure 7.10. A comparison of some of the 
quantitative aspects of these curves is given in Table 7.6. 
TheDSC curves (Figure 7.9) of the irradiated physical mixtures ofFRIBCD show some indication 
of the melting Idecomposition of the pure FR except at a high BCD proportion (1:3 FRlBCD) 
where neither the BCD dehydration nor the FR features appear. 
Irradiation of the kneaded mixtures results in the FR features being undetectable, although they 
are visible in the original kneaded mixtures. The changes are, again, greatest in the 1:3 FRlBCD 
mixtures. 
7.4.2 FRlGCD mixtures 
The thermal behaviour of both physical and kneaded FRlGCD mixtures, after irradiation for 16 
h at 550 W h m", was examined. The DSC curves for the physical mixtures are illustrated in 
Figure 7.11 and for the kneaded mixtures in Figure 7.12. These DSC results are compared with 
those for the unirradiated mixtures in Table 7.7. 
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Figure 7.9 DSC curves ofFRJBCD physical mixtures irradiated for 16 h compared with 
wlirradiated physical mixtures heated at 10 °C min-J in nitrogen. 
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Figure 7.10 DSC curves of FRfBCD kneaded mixtures irradiated for 16 h compared with 
unirradiated kneaded mixtures heated at 10°C min· t in nitrogen. 
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Table 7.6 Comparison of the thermal behaviour of irradiated samples ofFRJBCD mixtures with those of the original samples 
Samples Expected II.H II.H of dehydration FR melting range in II.H of dehydration of FR melting ! I 
I 
dehydration for of the of BCD in the the original 
, 
BCD in the irradiated range in the 
BCD proportion in the original mixtures / FRlBCD mixture / (16 h) FRlBCD irradiated (16 h) 
mixtures / J (g BCDyl J (g BCDY' DC mixtures / J (g BCDY' FRlBCD mixture 
/ DC 
FR standard - - 216-226 0 216-226 
FR irradiated 
- - -
0 220 DC 
I: 1 FRJBCD phy. 173 171 216 -223 172 212-218 DC 
I: I FRJBCD kn. 173 169 220-223 (32 + 23) = 55 not visible 
1:2 FRJBCD phy. 195 146 220-223 162 209-218 DC 
I 
, 
1:2 FRlBCD kn. 195 190 220-224 77 not visible I 
, 
1:3 FRlBCD phy. 203 172 219-223 Not visible not visible I I 
1:3 FRJBCD kn. 203 195 213-225 (67 + 17) = 84 not visible 
I 
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Figure 7.11 DSC curves ofFRlGCD physical mixtures irradiated for 16 h compared with 
unirradiated physical mixtures heated at 10°C min·1 in nitrogen. 
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Figure 7.12 DSC curves of FRfGCD kneaded mixtures irradiated for 16 h compared with 
unirradiated kneaded mixtures heated at 10 DC min" in nitrogen. 
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Table 7.7 Comparison of the thermal behaviour of irradiated samples ofFRJGCD mixtures with those of the original samples 
Samples Expected ill AH of dehydration FR melting range in AH of dehydration FR melting range in 
dehydration of ofGCD in the the original FRlGCD ofGCD in the the irradiated (16 h) 
GCD proportion original mixtures / mixture / °C irradiated (16 h) FRlGCD mixture / °C 
in the mixtures / J (g GCDY' FRlGCD mixtures / 
J (g GCDY' J (g GCDY' 
FR standard - - 216-226 0 216-226 
FR irradiated - - - 0 220°C 
1: 1 FRJGCD phy. 49 56 220 -226 52 220°C 
1:1 FRJGCD 1m. 49 (30 + 53) = 88 223-225 (6 + 13) = 19 not visible 
1:2 FRJGCD phy. 55 58 220-223 76 220°C 
1:2 FRJGCD 1m. 55 52 223-227 (17+ 13)=30 not visible 
1:3 FRJGCD phy. 41 62 219-223 73 220 
1:3 FRJGCD 1m. 41 virtually eliminated 237-255 68 not visible 
-
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The DSC curves for the irradiated FRlGCD physical mixtures (Figure 7.11) show indications of 
the thermal behaviour of irradiated pure FR (see Section 7.1 ) with the melting/decomposition 
feature broadened and shifted to a lower temperature. The above features were not observed in 
the DSC curves for the irradiated, kneaded mixtures (Figure 7.12). 
7.4.3 Discussion 
Physical mixing of FR with either BCD or GCD does not offer complete protection against 
changes in thermal behaviour resulting from irradiation. Some of the FR in the mixture is affected 
by irradiation in a similar manner to pure FR. The kneading process does change the properties 
of the mixture. 
Irradiation of both the FRlBCD and FRlGCD mixtures can results in changes of the dehydration 
behaviour of the cyclodextrin component. This could be due to the heating effects of irradiation. 
Generally mixing with cyclodextrins appears to enhance the thermal stability of FR. This is most 
evident for kneaded mixtures with GCD in high molar proportions. As is shown in Section 6.3, 
however, this mixing results in decreased photostability of FR. 
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7.5 X-ray powder diffraction patterns of irradiated FRIeD mixtures 
The X-ray powder diffraction patterns of irradiated FRJCD mixtures are compared with the 
patterns of the original mixtures in Figure 7.13. 
1:3 FRlBCO kn. mixture original 
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Figure 7.13 XRD patterns of a) the original 1 :3 FRlBCD physical mixture, b) the original 1:3 
FRJBCD kneaded mixture, c) a 1:3 FRlBCD physical mixture irradiated for 16 h and d) a 1:3 
FRlBCD kneaded mixture irradiated for 16 h all at 550 W h m·2, 
97 
1:3 FRlGCD phy. mixture original 
5 15 25 35 45 55 
AngleJdeg 
~ 
.. 
c: 
CI 
"; 
5 
1:3 FRlGCO kn. mixture original 
15 25 35 45 55 
angleJdeg 
1:3 FRfGCD phy. mixture irradiated 16 h 1:3 FRfGCD kn. mixture irradiated 16 h 
5 15 25 35 45 
angle/deg 
55 5 15 25 35 
angle/deg 
45 55 
Figure 7.14 XRD patterns of a) the original 1:3 FRlGCD physical mixture, b) the original I :3 
FRlGCD kneaded mixture, c) a 1:3 FRlGCD physical mixture irradiated for 16 h and d) a 1:3 
FRlGCD kneaded mixture irradiated for 16 h all at 550 W h mol. 
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There are large differences between the XRD powder patterns of the physical and the kneaded 
mixtures ofFRJBCD (Figure 7.13). Against this, the changes caused by irradiation (16 h) of the 
kneaded mixture are not easy to identifY. There are definite changes in the pattern of the irradiated 
physical mixture and these appear to be related to the changes produced by irradiating pure FR. 
7.6 Infrared spectroscopic studies 
The infrared spectrum of pure and irradiated FR and of the original and irradiated FRicyclodextrin 
mixtures were recorded as described in Section 6.5. The main features are summarized in Table 
7.8. 
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Table 7.8 IR absorption maxima for pure and irradiated (for 16 h at 550 W h m-2) samples ofFR and FRlCD mixtures 
Samples 1'( C=O)/ cm-I I'(CN-H)/cm-' I'(S02N-H)/cm-1 I' (S=O)/cm-I v(C-Cl)/cm-' 
FRpure 1668 3348.6 1321.4 1141.3 581.7 
FR (16 h) 1667 3338.2 1319.5 1136.5 576.8 
1:3 FRlBCD phy broad & less intense weak band weak band weak band 575 
original 
1:3 FRlBCD broad & less intense weak bands 1323 broad & less intense 573 
phy. 16 h 
1:3 FRlBCD kn. weak band disappeared disappeared weak band 575 ! 
original 
1:3 FRlBCD kn. 1656 disappeared disappeared disappeared 577 
16 h broad & less intense 
1:3 FRlGCD phy broad & less intense disappeared decreased in intensity no change decrease in intensity 
original 
1:3 FRlGCD 1657 disappeared 1371 1146 disappeared 
phy_ 16 h broad & less intense broad 
1:3 FRlGCD kn. disappeared disappeared disappeared disappeared decreased in intensity 
original 
1:3 FRlGCD kn_ 1652 disappeared 1367 1151 573 
16 h broad & less intense broad & less intense 
~--- ---
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From the results in Table 7.8 it can be seen that the main absorption maxima of FR are shifted 
after irradiation for 16 h. The spectra of the irradiated 1:3 FRlCD mixtures also some indicate 
changes compared with the unirradiated samples. The carbonyl stretch c=o in the 1:3 FRlBCD 
kneaded mixture irradiated for 16 h appears around 1656 cm-! and the s=o band had disappeared, 
even though it was visible in the unirradiated mixture. In the irradiated 1:3 FRlGCD physical 
mixture, the carbonyl stretch C=O appears around 1657 cm-! and the C-Cl stretch has disappeared 
even though it is visible for the original sample. For the irradiated 1:3 FRlGCD kneaded mixture 
the C=O band appears around 1652 cm-! and the NH2 band appears around 1367 cm-! and the S=O 
band is at 1151 cm-!, even though these bands were not visible in the spectrum of the original 
sample. These results indicate that irradiation causes changes in the drug and in the 
druglcyclodextrin mixtures. 
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7.6 UV/visible spectra of pure FR and irradiated FR 
The spectra shown in Figure 7.15 were recorded for solutions of pure and irradiated FR with 
methanol and water in 50/50 v/v. The concentration used was 5 mg 1-1 for all the samples. 
There was no significant difference between the spectra of these samples. 
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Figu re 7.15 UV Ivisible spectra of pure FR and FR irradiated for 16 hours 
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ChapterS 
8. CONCLUSIONS 
8.1 Furosemide forms 
Several different solvent-dependent, crystalline forms ofFR have been reported [20]. Fortunately 
most of the detailed studies have been based on the readily available, commercial form, Form I, and 
the sample used in this study was identified as this form from its X-ray powder diffraction pattern 
(see Figure 5.8) and its IR spectrum ( see Figure 5.5). 
8.2 Thermal behaviour of FR 
Furosemide undergoes an endothermic transition (about 2 J g") at about 138°C. The transition was 
found to be readily reversible on cooling. Melting occurs at about 222 to 226°C and is immediately 
followed by exothermic decomposition (about -J 07 J g") . Decomposition occurs in at least two 
overlapping stages ( this can be observed from the TG curve ofFR in Figure 6.1). TG-FTIR 
results showed that decomposition is still incomplete on heating at 10°C min" to 650°C and that 
major gaseous products evolved above 250 °c are S02 and CO2, 
The DSC and TG observations are in agreement with those reported by Doherty and York [19] 
(Figure 1), Beyers e/ al. [18] (Figure 1 and 2), Matsuda et at. [80] (Figure 3 (a», and Matsuda 
and Tastumi [20] (Figure 4 (a». Doherty and York suggested [19] that the small endotherm at 
about 138°C was due to a solid-solid transition from Form I to Form II. Ozdemir and Ordu [29] 
misidentified the en do/exothermic direction in their DSC traces (Figure 3), but otherwise the 
features are similar. 
8.3 Photostability of FR 
Furosemide has been reported [83] to degrade (both in the solid state in aqueous solution) with 
accompanying discolouration on exposure to light . De Villiers et al. [83] exposed samples ofFR, 
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Forms I and II, to sunlight, in the presence and in the absence of oxygen. The initial stages of 
degradation were acceleratory and the extent of degradation of Form II was generally greater than 
for Form I under the same conditions. They measured the extent of degradation ofFR in terms of 
the amount of the degradation product, 4-chloro-5-sulphamoylanthranilic acid (CSA), formed. In 
this study, only samples of Form I were irradiated. The atmosphere was air and the source of 
illumination was the Suntest cabinet (550 W h m-2). De Villiers et al. [83] described the 
acceleratory parts of their degradation curves by the power law with n = 2, i.e. : 
where a is the extent of degradation, his the rate coefficient, t is the time and C is a constant. In 
this study, the extent of degradation was determined from the amount ofFR remaining. A plot of 
II y, against time is shown in Figure 8.1. From linear regression ( R2 = 0.9942), the value of t 
is 0.0206 ± 0.0009 h- I which is not too different from the £ values for sunlight reported by De 
Villiers et al. [83] (Form I in oxygen: 0.0148 h -I) . 
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Figure 8.1 Application of the power law with n = 2 to the extent of photo degradation ofFR with 
time of irradiation at 550 W h m-'. The original data are shown in Table 7.1 
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8.4 Thermal behaviour of irradiated FR 
DSC and TG curves for samples ofFR that had been irradiated for 16 h (at 550 W h m .2) showed 
considerable differences in the thermal behaviour from that of the original drug (see Section 7.1). 
The DSC and the TG curves, for the dark control samples, which were shielded from irradiation 
under aluminium foil, did not show any significant changes from those of the pure drug. The 
products of photo degradation either catalyze the thermal decomposition ofFR in the solid state or 
lower the melting point of FR so that thermal decomposition in the melt is enhanced. 
8.5 Thermal behaviour of mixtures of FR with cyclodextrins 
As expected, the kneading procedure, using ethanol as the solvent, produced mixtures that showed 
more reproducible behaviour than simple physical mixing of the samples. The ethanol treatment 
does not have much effect on the water content of the cyclodextrins. 
A strong indication of inclusion ofFR in the cyclodextrin cavity was observed in the 1:3 FRlGCD 
kneaded mixture, where the melting of furosemide was not observed at its normal temperature (i.e. 
222-226) DC, but two endotherms around 237-255 DC were observed which were not in the DSC 
curves for GCD. Changes in the IR spectra supported the occurrence of inclusion. The XRD 
powder pattern of the 1:3 FRlGCD kneaded mixture was observed to be different from the patterns 
of the drug alone, ofGCD and of the 1:3 FRlGCD physical mixture. 
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8.6 Photostability of mixtures of FR with cyclodextrins 
Comparison of the results of irradiation of samples of the FRicyclodextrin mixtures for 16 hours 
at 550 W h m", with those for pure FR under the same conditions, shows that the mixtures with 
cyclodextrins have a decreased photostability. While pure FR degrades by about 11 %, the 1:3 
FRlGCD kneaded mixtures showed 57 % degradation and the 1:3 FRlBCD kneaded mixture 
showed 21 % degradation. 
The interaction between FR and GCD, indicated by the thermal and spectral results for the 1:3 
FRlGCD kneaded mixture, does not stabilize the drug towards exposure to light. This may 
indicate that the light-sensitive moiety of the drug molecule is outside the CD cavity, even if a 
considerable portion of the molecule is included, and so mixing with the cyclodextrin may result in 
an increase in the photodegradation of the drug. 
Even though a full molecular modelling study was not attempted, some qualitative conclusions can 
be drawn. The diameters of the cavities in the two cyclodextrins used were different: 0.8 om for 
BCD and 1.0 nm for GCD . (See Figure 8.2 [55] and also Figures 4.1 and 4.2) The crystal 
structure ofFR has been reported by Al-Obaid et al. [3]. A diagram of the optimized molecular 
structure of FR, prepared using the semi-empirical PM3 approach in the Spartan molecular 
modelling program shown in Figure 8.3. Some of the major dimensions of the FR molecule are 
given in Table 8.1 (based on the numbering given in Figure 8.2). 
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Figure 8.2 Illustration of the approximated diameters of beta-cyclodextrin and gamma-
cyc10dextrin cavities [55] 
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Figure 8.3 Optimized molecular structure ofFR, prepared using the semi-empirical PM3 approach 
in Spartan molecular modelling program. 
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Table 8.1 Some of the major dimensions (in A) of the FR molecule based on the numbering in 
Figure 8.3 
ClltoNI 9.36 
o I to C I 6.80 
N2toCll 4.57 
C2toCII 4.90 
N 2 to S 6.10 
It would appear unlikely that the FR molecule would be totally included, even in the larger GCD 
cavity. The space available for inclusion is doubled in the head-to-head alignment of two CD 
molecules [85] (Figure 8.4) but, presumably, such an arrangement would require a more 
symmetrical guest molecule than that of FR 
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Figure 8.4 Schematic representation of the different packings of the structures ofbeta-cyc1odextrin 
dimers, with (a) showing the head-to-head channel alignment, (b) head-to-channel-type, (c) the 
cage-type, (d) the layer-type and (e) the layer-type composed of BeD dimers [85]. 
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Some of the possible modes of partial inclusion of large (and unsymmetrical) guest molecules are 
discussed by Osa and Suzuki [86]. Most of the examples quoted show ready inclusion of the 
phenyl ring. 
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